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In the last decade nanotechnologies have greatly developed in many research fields
such as engineering, electronic, biological and many others. They can offer several
possibilities to design tools, to create new techniques or improve the already existing
ones, to discover innovative applications. And nanotechonology research is just at the
beginning.
One of the most interesting thing of this topic is the size of nanostructures. These
materials are thousand times smaller than a cell and have a compatible size with
proteins, enzymes and a lot of biological molecules.
For this reason many research groups specialized in biotechnology started to invest
people and resources in this new scientific possibility. Following this very promising
trend, BIOtech, a research group for biotechnology at the University of Trento, has
proposed the Nanosmart project.
Developed together with many prestigious institutes all over the world, this project
aims to exploit the nanotechnology possibilities in biological research.
The purpose of this challenge is the design, development and production of mag-
netic nanoparticles to use them in diagnostics and therapy of cancer disease.
Magnetic nanoparticles (MNP) are spherical agglomerates of iron oxide, few tens
of nanometers, which can be exploited in many ways. Being magnetic they can
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6 Introduction
be used as contrast agents in magnetic resonance imaging MRI. Together having a
high absorbing coefficient in the radio frequency band, they can locally increase the
temperature of the tissues hosts and this being used for hyperthermia treatments.
Entrapping some drugs in one of their multilayers, MNP can be used as inert
carriers for drug delivery: due to their small size they can enter biological tissues, cross
the plasma membrane of cells and release the drug only on predetermined targets.
My Ph.D. started together with the project; so I had the possibility to follow this
research from the beginning. In this years many problems have been handled, many
errors have been made, many brilliant ideas have been shelved but also new abilities
have been acquired, important collaborations were born and alternative structures
have been thought and, fortunately, realized.
Trying to eliminate unnecessary things and focusing on main purpose of this work,
in this thesis I want to illustrate just the long “fil rouge” that connects the idea of






On Nanoparticles and their
Application
Starting a new project is always a new challenge also for a laboratory with great
experience. Challenge that becomes more charming when the topic of the project is
almost totally new. One of the first difficulty is to acquire knowledge of the state
of art of the topic and to use literature to get know how to handle research with
the best possible performance; this permit to save time and money, to avoid useless
experiments and, hence, to focus on changes and evolutions of tests already carried
out and well documented in the scientific literature.
To better understand what are the properties characterizing magnetic iron oxide
nanoparticles (MNPs), we need to deepen their purpose and usage. For this reason
it is important to learn the possibilities offered by field of nanotechnology and its
applications in diagnosis and therapy for medicine, in particular those offered by
nanoparticles. Most of the attention will be on magnetic iron oxide nanoparticles
9
10 CHAPTER 1. ON NANOPARTICLES AND THEIR APPLICATION
(simply called MNP) in particular on their composition, structure, characterization,
functionalization and analysis.
Taking into account these properties and characteristics of MNP, University of
Trento, in collaboration with other six research centers from different countries, car-
ried on the “NANOSMART” project, which at the use of nanoparticles in diagnosis
and therapy of tumors.
1.1 Nanoscience and Nanotechnology
In the first studies and in earlier publications, the terms “nanoscience” and “nan-
otechnology” had quite similar meaning. As years goes by the two terms have taken
slightly different meanings. Nanoscience is the study of phenomena and manipulation
of materials at atomic, molecular and macromolecular scales, where properties differ
significantly between these scales and major scales. Conversely, nanotechnology refers
to the design, characterization, production and the application of structures, devices
and systems for the control of the form and size of nanoscale components.
The prefix nano comes from the Greek word νανφς. A nanometer (nm) is equal
to one billionth of a meter, 10−9m. A human hair is approximatively 80 thousand nm
wide, while a red blood cell approximately 7 thousand nanometers (Figure 1.1). Atoms
are smaller than a nanometer, while some molecules, such as proteins or antibodies,
are compatible with this size.
The main effects that characterize the properties of nanoparticles compared to the
same material at the macroscopic scale are two: size-dependent and quantum effects.
Nanosciences study how they affect the properties of materials, while nanotechnologies
aim to exploit this peculiarity to create structures and systems with new properties
and functions by modulating these effects as desired.
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Figure 1.1: Size scale, for each dimension is represented a characteristic structure [1]
The use of nanocomposites is very ancient; for instance, already in the tenth
century, nanoscale pigments were used to color glass and ceramics. But it is just in
recent years that the necessity to investigate and manipulate nanoscale materials has
led an improving and evolution in consideration and in design of instruments that can
exploit these possibilities.
The highest leap forward in this research field was designed and developed in the
80’s with the design of two instruments: the scanning tunneling microscope (STM) in
1982 and the atomic force microscope (AFM) in 1986. These apparatus use nanomet-
ric approach to produce atomic resolution images. They also have the ability to move
atoms or molecules on surfaces, building rudimentary nanostructures; one of the most
famous example is the word IBM made by Eigler and Schweizer in 1990 (Figure 1.1).
Nanomaterials can be constructed with top down or bottom up approaches. With
top down very small structures are produced starting with a large part of mate-
rial through processes of mass removal. On the contrary, with bottom up technique
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nanoscale materials is produced building up atom by atom, molecule by molecule.
The evolution of this technique is self-assembling, in which the atoms or molecule are
able to create structures according to their natural properties. Another aspect of the
bottom up technique is the use of tools that can move individual atoms or molecules.
Figure 1.2: The convergence of technique production “top-down” and “bottom-up”
[1]
The main challenge of top-down method is the creation of small structures with
sufficient precision, while for bottom-up is the creation of large structures with a
good quality and resistance that can be used as a material. These two methods have
evolved separately but the objective was always the same: the production of nanoscale
structures.
In recent years the scientific community is trying to develop a hybrid technique
able to take the positive aspects of both methods. Nanosciences and nanotechnologies
encompass a large number of fields: chemical, physical, biological, medical, engineer-
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ing and electronics. The four main subdivisions of nanosciences are: nanomaterials,
nanometrology, bionanotechnology and optoelectronics for information and commu-
nication.
The current applications of nanomaterials include the use of these materials as thin
films of coverage, for example, in electronics and as active surfaces such as windows
self-cleaning. In most cases nanoscale materials are bound or placed on some supports,
but some types of nanoparticles are used free, as in commercial sunscreen. The
particles of these creams have a composition able to absorb the ultraviolet rays UV
of the sun, to protect the skin from diseases carried by a typical long exposure to
sunlight. The skill and the precision of the production of nanomaterials, with size
less than 100 nm, are so high to bring benefits in the production of components in
various fields such as information technology and automobile and aerospace industry.
In the coming years nanomaterials will increase performance in a variety of products
such as silicon electronics, displays, paints, catalysts and microsensors.
Are also very promising carbon nanotubes, hollow tubes products with carbon
molecules which have a great resistance, a good flexibility and great electrical con-
ductivity; probably they will revolutionize the field of electronics and communications.
In the future lubricants based on inorganic nanospheres will be used; they are mag-
netic materials that take advantage of nanocrystalline grains, medical nanoceramics
that have more durability and better prosthetics applications and nanomembranes
for a better water purification. Nanometrology, which is the science of measurement,
can be used by nanotechnology because it allows the morphology and electric char-
acterization of a lot of materials.
Regarding the optoelectronic information and communication, nanotechnology is
making great strides. An example is the evolution of the size of a transistor from
90 nm in 2004 to future 22 nm in 2016. Other applications are the use of magnetic
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materials for the storage of data. In information technology field nanoscience were not
limited only to the electronics of silicon, for example the use of plastic electronics to
produce flexible displays. Quantum dots are semiconductor nanoparticles developed
in recent years; they can be adjusted to emit or absorb light of a particular color for
use in solar cells or in the fluorescence labeling for biological experiments.
Applications of nanotechnology in medicine are especially promising, with several
areas of study as the diagnosis of diseases, the drug delivery in specific areas of the
body and molecular imaging. In medical field, research seeks to produce materials
and tools as a scaffold for cell and tissue engineering and sensors that can be used
for monitoring of human parameters. In the coming years nanotechnology can help
to produce complex structures as the retina and cochlea and using biotechnology it
will be easier to understand how complex biological structures are composed. [2]
1.1.1 General introduction on nanomaterials
Nanomaterials are defined as those structures that do not even have all dimensions in
the nanoscale. For example, there are some materials, such as films or coating surfaces
of computer chips, which are nanoscale only in one dimension and the other two are
macroscopic. Nanotubes or nanowires are examples of 2-dimensional nanostructures
with nanometer scale. With regard to compounds that have all three nanosized, there
are colloids, precipitates and quantum dots. In this definition it is possible to find
also materials with macroscopic scale; they are nanocrystalline materials made of
nanometer-sized grains.
Materials that have well defined physical properties, at the nanometer scale, can
express quite different properties; an example is the copper, that is malleable and
ductile, which, if produced in spheres or tubes of size below 50 nm, completely loses
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its malleability and ductility becoming a very hard material.
As already mentioned, the two main factors that give different properties of
nanoscale materials are the increase of the ratio between surface and volume and
quantum effects.
Fundamental properties for a material, as surface reactivity, resistance and elec-
trical characteristics are size-dependent and that depends on the number of atoms
on the surface respect to total amount of atoms while for a microstructure this ratio
between surface atoms and total atoms tends to zero. For instance a particle with size
of 30 nm has 5% of atoms on its surface, while at 10 nm are 20% and for nanoparticles
with size of 3 nm on the surface atoms are the half of the total.
So a material will be very more reactive in its nanometric form compared to the coarse
one.
Quantum effects modify optical, electrical and magnetic properties; the effect is
more significant decreasing the size of the object. In some cases a very small size
can also modify the mechanical properties; this happens in metals made of small
crystalline grains. The neighboring regions of these grains slow or completely stop
the propagation of defects when the material is stressed. If the grain are nanometric,
the number of interaction between them becomes huge increasing the effectiveness
of the material under stress. For example, in experimental tests the nanocrystals of
nickel resulted to be much more resistant than the steel, the harder one.
One nanometric dimension
Materials with one nanometric dimension, such as films and active surfaces, have been
developed and used for decades in electronics, chemistry and engineering; probably
greatest development occurred in the industry of silicon integrated circuits. The
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monolayer thickness of an atom or molecule, are frequently used in chemistry. The
formation and properties of these layers can reasonably be understood from an atomic
point of view, even in the case of complex layers, such as lubricants. Progress has
been made in controlling the composition of the surface polishing and the film growth.
The engineering of surfaces, such as the choice of the size or modulation of reac-
tivity, finds many applications as cells with fuel or catalysts. The large surface area,
full of nanoparticles, can be used in many applications, especially in the chemical and
energy sector where the great reactivity and selectivity is exploited to save money
reducing the main resources for the production of energy.
Two nanometric dimension
Research and investigation of nanostructures with two nanoscale dimensions is quite
recent, about the last 15 years. The interest increased when the first results em-
phasized the great Electrical and mechanical properties of these structures. Carbon
nanotubes (CNTs) are graphene sheets and are of 2 types: single wall, a single tube
or multi-wall, a series of concentric tubes, as shown in Figure 1.3. In both cases,
the diameter is a few nanometer and the length ranges from several micrometers to
few centimeters. Nanotubes are mechanically very strong: indeed, the value of the
Young’s modulus is greater than 1 terapascal, very similar to diamond. In addition
to the mechanical strength, they are very flexible and are good electrical conductors;
actually they behave like semiconductors or metals.
Applications of carbon nanotubes are several: the reinforcement of composite ma-
terials, nanoelectronics, sensors and displays. In addition to the carbon nanotubes
there are nanotubes of inorganic compounds of molybdenum disulfide; they have ex-
cellent properties as lubricants, high impact resistance and high reactivity in catalytic
capability to store oxygen and lithium. Nanotubes based on oxides, such as titanium
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Figure 1.3: Single-wall or multi-walled carbon nanotubes [1]
dioxide, may instead find good applications in the field of catalysis, photocatalysis
and energy storage.
Another example of materials with two nanometric dimensions are nanowires.
These structures are composed of incredibly thin cables, or even by a linear series
of points, self-assembled. Nanowires can be produced by a wide range of materials,
such as silicon, gallium nitrate, and the indium phosphide. These structures have
been shown to have magnetic, electronic and optical properties; for example silicon
nanowires can bend the light also around a narrow angle. For these reasons, the
applications of the nanowires are different as the storage of data at high density
for magnetic heads for writing on electronic media, for electronic devices and opto-
electronic and metal interconnections between quantum devices and nanodevices.
Three nanometric dimension
All three dimensions of this kind of material are nanometric and as a consequence
the volume of these structures is contained in a sphere-form structure with a size less
then 100 nm. The main structures of this type are fullerenes, dendrimers, quantum
dots and nanoparticles especially.
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This is only a short introduction on nanoparticles. Next section provides a deep
description of them.
1.2 Nanoparticles
Nanoparticles are aggregates of molecules with a size less than 100 nm. The term
nanoparticle is extended to include sub-categories such as nanopowders, nanoclusters
and nanocrystals. Nanocrystals are compounds with a crystalline form and a size
less than 100 nm. Nanopowders and nanoclusters are compounds that do not have
a crystalline form and which have, respectively, size less than 100 nm and between 2
and 10 nm with a very narrow size distribution.
There are many type of structures, the most important are four.
Nanoparticles
These compounds exhibit new and interesting properties that depend on the size,
which is less than 100 nm. Nanoparticles are widely present in the natural world as
photochemical reactions, as result of volcanic activity or produced by plants or algae.
They have also been created, unintentionally, by humans in the form of products
of combustion residues and cooked food or, more recently, as the remains of the
exhausted fuel of vehicles. In comparison to the quantity of nanoparticles produced
naturally or accidentally, nanoparticles synthesized for research or industrial purposes
are a small minority. This minority increased in recent years and will grow even
more in the next, thanks to developments that these special size-dependent properties
carried out in the various fields in which they are exploited. For example, titanium
dioxide or zinc oxide become transparent if they form nanometer-sized structures and
absorb and reflect UV rays.
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Nanoparticles have a large range of applications: in a short time in the cosmetics
industry, textile and paint industries; in long times such as contrast agents for diag-
nostic imaging or carriers for drug delivery and hyperthermia. Nanoparticles can be
arranged in layers placed on top of other structures, increasing the surface and im-
proving the reactivity, finding many applications in the field of catalysts. Currently,
nanoparticles are not produced for direct use, but they are exploited as additives or
ingredients in already existing products, in order to improve some properties. The
diffusion of nanoparticles is very low compared to other nanoscale materials, because
there is not yet in-depth information of their toxicity. Toxicity, that can be decreased
attaching them on the surface or binding with other composites. In fact, if nanopar-
ticles are free or attached, you can have different impacts on health and safety man
or nature if the nanoparticles are free or bound to other molecules or structures. [19]
Fullerene
In the mid-80’s was discovered a new class of materials based on carbon called
fullerenes: “carbon 60” (C60) is the most famous (following figure).
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This is a spherical molecule of 1 nm in diameter with 60 carbon atoms distributed
in 20 hexagons and 12 pentagons; this is the same configuration of a classic soccer
ball. The term derives from the name of the architect Buckminster Fuller became
famous for the construction of geodesic domes.
A technique to produce large quantities of fullerene consists in heating small rods
of graphite in environment helium. There are many applications of fullerenes: as
lubricant for surfaces, carrier for drug delivery and electronic circuits.
Dendrimers
Another structure with all nanoscale dimensions is the dendrimer.
Dendrimers are highly branched molecules, which are characterized by their structural
perfection; in fact the name comes from the greek term dendron, which means tree
(following figure).
The structural perfection is based on evaluation of the symmetry and polydis-
persity. The dendritic molecules can be divided into low and high molecular weight
species. The dendimers are formed through a process of hierarchical self-assembly at
the nanoscale. There are various types of these molecules: the smaller have size of
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several nanometers, and are used in conventional applications such as coatings and
inks, but can be exploited as molecular carriers for drug delivery or as a filter to trap
metal ions for purify water, for example. [4]
Quantum dots
Quantum dots are semiconductor nanoparticles; they have been theorized in the 70’s,
but were created only in the 80’s.
If the particles of semiconductors are small, quantum effects come into play, be-
cause the surface is not more homogeneous but shows electrons or area of absence of
charge. The energy of these particles depends on the wavelength of the quantum state
that characterizes the surface and the color yields information on their size. More-
over, the quantum dots can be produced in order to absorb and emit the required
wavelength, just modifying the size. In the following figure the different absorptions
of quantum dots.
Recently, semiconductor particles have found applications in the field of compos-
ites, solar cells and as a tool for biological fluorescence analysis to trace the behavior
and localization of biological molecules. In all these fields the quantum dots can be
prepared to emit at certain energy levels. The latest developments have resulted in
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the production of high quality particles, coated, monodisperse and crystalline that can
reach dimensions smaller than 2 nm in diameter, which can be exploited as marker
in the treatments of chemical reagents or processes. [4]
1.2.1 Properties, Characteristics and Applications
Nanoparticles have great scientific interest because they have behaviors that are
halfway between those in macroscopic and the atomic or molecular scale. The me-
chanics regulating the interaction of nanoparticles with themselves are complicated.
For instance, a suspension of nanoparticles is possible because the interaction of the
their surface with the solvent is strong enough to prevail on the density difference,
which would push the nanoparticles to precipitate or float in the solvent.
The interaction between surface and solvent also depends on their polar or non-
polar nature.
There are two meaningful examples; the first concerns nanoparticles coated with
hydrophobic molecules. It is very easy to suspend this NP in a non-polar solvent
as toluene, consequently it is impossible to resuspend them in polar solvent as water
(figure 1.4). The second is about nanoparticles that have specific surface charge. They
can be suspended only in solvent with compatible amounts of ions, in the reverse case
the NP agglomerate and precipitate.
Nanoparticles also have properties in the visible because they are small enough to
confine their electrons, that produce quantum effects.
Those are the main properties of nanoparticles; there are many other properties
but they depend on the material and production process of NP.
Although it is impossible to determine what are the advantages and disadvan-
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Figure 1.4: Iron oxide core of nanoparticles in water (left) and in toluene (right)
tages for each type of nanoparticle, it is interesting to analyze which are the common
positive and negative characteristics. Among the positive properties there are tensile
strength, hardness, stability in the size, conductivity and thermal expansion, chemical
resistance and the ablation and the ability to strengthen. With regard to the negative
aspects have to be reported the increase of suspension viscosity, the emission in the
visible light, the great opacity and sedimentation.
The fields of study and research and applications of nanoparticles are several rang-
ing from engineering to quantum physics of materials, from biology to computer sci-
ence, from specific purpose in particular experiments to commercial use for everyday
objects.
In-depth illustration of main research and industrial fields where NP are used
would take a entire book probably, so that is just a table list of most recent applica-
tions: sunscreen and cosmetic, composites, buildings clay, optoelectronic, industrial
glass coating and protection, painting, fuel cell, display, ceramics, sensoring. [4]
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1.2.2 Biomedical application
Probably the most interesting area for nanoparticles application and the field where
their use and their research is more developed, especially in the last 10 years, is the
field of biology and medicine.
At the base of living organisms are the cells, which have a characteristic dimension
of about 10 µm. The structures that constitute cells are reaching a sub-micrometer
size. The smallest structures are proteins which have size of about 5 nm, which is
compatible with the size of a nanoparticle synthesized in the laboratory.
This simple dimensional comparison suggests to use nanoparticles as probes to
analyze and mimic the mechanisms and interactions that occur within the cell without
causing too much interference. Better understand how biological processes occur at
the nanometer level is one of the primary goals of bio-nanotechnology. The properties
of nanoparticles are several but those that have interest in biomedical practice are
those that depend on the size, such as optical and magnetic effects.
More studied biomedical application and with the best results for future are:
• Fluorescence bio-marker [5][6]
• Controlled drug release and gene therapy [7][8]
• Photegenic bio-sensors [9][10]
• Genetic structure probe [11]
• Tissue engineering [12][2]
• Hyperthermia [13][19]
• Separation and purification of bio-molecules or cells [14]
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• MRI contrast agents [15][16][17]
• Phagokinetic tracks [18]
As previously mentioned, nanoparticles and proteins have comparable size, this
means that nanomaterials may be adapted for mark or label biomolecules.
Labeling different molecules or cells, you can exploit the different sizes of nanopar-
ticles or bind NP on the structure surface that interact with them. These interactions
modify the structure of the ligands that can be viewed with ultraviolet or fluorescence
probes.
Ligands can be contained in the NP external layer (polymers, proteins, small
molecules); this is a further properties for the external shell beyond make NP bio-
compatible. To exploit optical properties of nanoparticles, fluorescent molecules can
be bind in the outer layer to change optical characteristics.
The approach used for the design and definition of a nano-biomaterial is repre-
sented in Figure 1.5.
Basically, in most cases the structure of nanoparticles is obtained with one or more
layer. The NP core (or inner layer) gives to NP the main characteristics or properties
(for iron oxide NP is super paramagnetic behavior). The outer layer can be exploited
to form bonds with other molecules, inorganic or polymer for example. These struc-
tures can be represented as nanovesicle or layer surrounding the nanoparticle. The
general forms are spherical and cylindrical, but many other shapes are possible.
The size and the size distribution especially are very important in some cases when
the nanoparticles are designed to penetrate through the cell membrane, for example;
an incompatible size of NP can cause a complete lack of penetration inside the cell.
These two parameters are essential when size dependent quantum effects are used to
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Figure 1.5: Configuration scheme used applied to medical or biological problems in
biomaterials approach [20].
control some properties of the materials. An average size very precise and a narrow
distribution are required to have very efficient fluorescence probe.
The outer layers may be multifunctional; combining magnetic and luminescent
properties it is possible to detect and manipulate various types of particles. The core
of these biostructures is often protected by several monolayers of inert materials, such
as silicon. For this reason organic molecules are absorbed or chemio-absorbed on the
surface of the nanoparticles, and the same layer can act as a biocompatible material.
However, very often an extra layer of ligands is necessary to proceed with further
functionalization.
The ligand is a molecule that has reactive groups on both ends. A group is
specialized for binding with the nanoparticles, the other for binding to biocompatible
molecules, such as dextran or poly-ethyleneglycol (PEG), antibodies, fluorophores
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and other molecules which depend on the function required by the application. [20]
Diagnosis using nanoparticles
One of main biomedical applications for nanoparticles is diagnosis to understand and
analyze the symptoms of diseases. These tools are used for several activities such as
to determine tissue type prior to organ transplantation, to determine blood type for
patients requiring blood transfusions, and to monitor the progression of disease and
the effects of therapy. It would be ideal the diagnosis of diseases before appearance
of symptoms. Catching a disease early would allow the patient to take appropriate
precautions to slow, halt or possibly reverse the progression of the ailment. It will be
possible to use diagnostic tests and genetic screening at the same time to have the
possibility of personalized therapy.
A general list of diagnosis application can be filled with:
• Screening for blood transfusions
• Monitor therapy activity
• Check disease progression
• Personalized medicine
• Genetic screening
• Diagnose disease susceptibility, risk assessment
• Infectious disease assessment
• Tissue typing for organ transplants
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One of last ideas is to perform a combination of techniques or tests with the
same nanotechnology tools or probe to perform accurate diagnosis. Current diagnos-
tic techniques include immunoassay, genetic-based tests, cell-based assays, tissue or
histological tests and medical imaging.
Until now the research fields with best results about use and application of nan-
otechnology and in particular nanoparticles are tissue engineering, drug discovery,
drug delivery and diagnostics . Nanotechnology is enabling a variety of diagnos-
tic methods, including optical, electrical, magnetic, electrochemical and mechanical
Functionalized nanoparticles can enable multiplexed bioassays for simultaneous diag-
nostic screening of multiple diseases High-capacity screening and combined molecular
and immunological diagnostics will play a role in establishing a broader range of test-
ing capabilities. Finally, smart nanostructures such as nanotubes, dendrimers and
nanoparticles are designed and fabricated with capability for diagnosis and therapy
[3][21][22][23][24][21][25][26]
For each diagnosis technique a lot of nanotechnology structures can be used; main
methods are described in following bullet point:
• Optical : enhanced fluorescence, quantum dots, surface plasmon resonance (SPR),
nanoparticles, nanoshells and fiber optics;
• Raman spectroscopy : surface enhanced Raman spectroscopy (SERS), tip en-
hanced Raman spectroscopy (TERS) and gold nanoparticles;
• Electrical : potentiometric, amperometric, conductimetric, enzymatic and nanopar-
ticles for hyperthermia;
• Mechanical : nanocantilevers, surface acoustic waves (SAWs) and quartz crystal
balance;
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• Mass spectrometry : nanoparticles pre-concentrator
• Magnetic: immunoassay, magnetofection and magnetoresistive
• Imaging : constrast agents nanoparticles and multifunctional agents
• Genetics: nanopore sequencing and nanoparticles carriers
• Immunoassays: luminescent nanoparticles
A lot of structure in biological system have nanoscale size. Viruses, proteins, small
molecule drugs and fluorescent dyes are all less than 100 nm, as shown in fig. 1.1
Through the manipulation of organic and inorganic materials at the atomic level, novel
materials, structures and devices can be realized enhancing thermal, optical, electrical
and mechanical properties of materials. Properties of materials at the nanoscale can
be quite different than bulk material properties. For example it is possible to modify
surface properties of materials, such as adhesion. As explained, the great surface
area per unit volume of nanomaterials exhibits higher chemical reactivity, increased
mechanical strength, and faster electrical and magnetic responses.
Medical applications show particular promise, including building blocks of nucleic
acids as structural components as binding agents similar to antibodies rather than
typical genetic maps, nanostructured biosensors for implantable patient monitoring
and nanoparticles as imaging contrast agents.
The three big categories of diagnostic are: assays, bio-sensors and imaging. The
first purpose for nanotechnology is to improve the already existing test and, in the
future, to create novel diagnostic methods. [27]
In vitro assays are used extensively for diagnostics. Assays are used for: enzyme-
linked immunosorbent assays (ELISAs), polymerase chain reaction (PCR)-based ge-
netic assays and staining assays such as Giemsa and Gram for viral and bacterial
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diagnostics.
With a disease that needs diagnostic assay, patients sample would be shipped to
laboratory and analyzed; nanotechnology aims to reduce this procedure in order to
increase test sensitivity and to catch a disease earlier.
Research on biosensor aims to exploit the acknowledgment of assays and transfer
it to design implantable devices for better and faster diagnosis. Nanostructures can be
used to enhance these transduction mechanisms. For example, quantum dots can be
used in optical biosensors. They are more photostable respect to traditional organic
fluorophores, they ave greater quantum efficiency and have much narrower emission.
The main advantages could be in use such as high sensitive optical biosensors and
multiplexed assays. Functionalized magnetic nanoparticles can be targeted to desired
analytes and detected with miniature magnetic sensors, creating portable diagnostics.
Medical imaging for diagnostics include X-ray imaging, computed tomography
(CT) scans, magnetic resonance imaging (MRI), positron emission tomography (PET)
scans, ultrasound and more recent optical techniques such as optical coherence tomog-
raphy (OCT).
The advantage of imaging over assays and biosensors for diagnostics is the elim-
ination of the need for a patient sample, such as blood or tissue. So, they are not
invasive totally. However, most medical imaging equipment is expensive and requires
trained personnel to operate and interpret results. Another disadvantage is the low
resolution of most of these techniques that limits sensitivity. Nanoparticles as contrast
agents can be used to increase sensitivity which may allow earlier diagnosis of dis-
eases or keeping the same sensitivity it is possible to reduce size and cost of diagnostic
instruments, tools and apparatus. [28]
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Nanotechnology properties to improve diagnosis
As described, there are a lot of possibilities, methods and characteristics of nanotech-
nological material to improve quality and effectiveness of diagnosis. In this part of
this work the focus will be only on these properties showed by iron oxide nanoparticles
that have been developed for this Ph.D reasearch.
All properties of three nanometric dimension structures are numerated in the








Fluorescent: tags with this characteristic, such as fluorescein isothiocyanate
(FITC) and rhodamine, have been used extensively as optical markers for a variety of
biological assays. Traditional fluorophores have a broad user base and are available
in many forms such as voltage-sensitivity dyes, membrane-specific chemistries and
pH-sensitive structures. However, traditional fluorophores have some typical disad-
vantages: broad emission spectra, short emission lifetimes and photobleaching. Nan-
otechnology can improve use of traditional fluorophores and develop novel markers
to transform optical detention methods with greater sensitivity, multiplexed assays,
single-molecule detection and in vivo diagnostics. Fluorescent tags can be improved
32 CHAPTER 1. ON NANOPARTICLES AND THEIR APPLICATION
by conjugation with receptor molecules, with coatings for improved photostability,
and by combining with metals for greater emission. For example, nanoparticle plat-
forms consisting of surface-functionalized, silica-coated nanophosphors can be used
for bioimaging applications Silica coating enhances aqueous dispersion of nanoparti-
cles, and allows surface functionalization of peptides and nucleic acids for specificity.
Fluorescence emission can be tuned by controlling the size of the nanoparticle. A
range of nanoparticle sizes can be used simultaneously for multiplexed assays due to
each size of nanoparticle emitting a different color. [20][29][30]
Fluorescent is a great nanomaterials property, but not all materials have that
property even if they are in nanometric form. As already said, nanoparticles have
a great superficial reactivity so it is very easy to bind different molecules on their
surface. One of this molecule could be a fluorescent dye; a non-fluorescent nanoparticle
functionalized with a dye becomes a fluorescent probe to all intents and purposes.
This is the case of iron oxide nanoparticles used in this work. Iron oxide core does
not emit fluorescent signal and to obtain a fluorescent nanoparticles probe it has
been used a specific dye: DiI (fig. 1.6). The protocol, application and result of this
procedure will be described in following parts of this work.
Magnetic: several structures exploit their magnetic properties for specific pur-
pose. One of the most studied is magnetic separation: functionalizing NP with lig-
ands that can bind specific molecules, it is possible to use a magnet to separate these
molecules from oher molecules in solution. It is possible to use ferrite nanoparticles
coated with gold or silica. Antibody-conjugated magnetic nanoparticles can be used
to tag proteins for magnetic immunoassays Another application is binding RNA or
DNA for sensoring: molecular beacons can be bound to magnetic nanoparticles to
enable capture of single-base mismatched DNA and target mRNAs for intracellular
gene expression analysis (Fig. 1.7)
1.2. NANOPARTICLES 33
Figure 1.6: Structure (left) and absorption-emission spectra (right) of DiI fluoresent
dye
Combining molecular beacons with magnetic nanoparticles, single-base mis- matched
DNA can be magnetically separated (Fig. 1.26)
Another application is exploiting of magnetic skill of nanoparticle to move them
inside the cell; in addiction to this, functionalized magnetic nanoparticles may also be
internalized through magnetofection: the application of external magnetic to attract
magnetic nanoparticles into the cell. [32][33][34]
Also sensoring can use magnetic nanoparticles could also be used for benchtop and
handheld diagnostics similar to chip-based electrical methods for biological analysis,
in particolar for tests regarding DNA. This instrument works in a similar way of
atomic force microscope (AFM), but instead of electric interaction, this tool can map
the magnetic signal of nanoparticles.
Medical imaging diagnostic techniques represent one of the most interesting re-
search field about nanoparticles; they include MRI, PET, CT, OCT, optoacoustic or
photoacoustic tomography (OAT or PAT) and NIR imaging. Nanoparticles contain-
ing hundreds of contrast agents can greatly enhance the sensitivity of these imaging
methods Examples of MRI contrast agents include gadolinium-diethylene-triamine-
pentacetic acid (Gd-DTPA) and superparamagnetic iron oxide particles (SPIOs).
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Figure 1.7: Magnetic nanoparticle tagged with molecular beacon oligonucleotide
structure [1][31]
[36][37]
Ultrasound contrast agents are designed to affect the propagation of sound waves
in the surrounding sample area by altering the acoustic properties. Liquid perfluoro-
carbon nanoparticles and liposomes are examples of ultrasound contrast agents.
The first advantage to use nanoparticles in the nanometric size, is that they can
prolong the time before elimination by the body because big structures activate the
inflammatory response earlier respect to nanostructure.
Noninvasive detection at the single-cell level may be possible with nanocarriers
loaded with contrast agent and functionalized with biological receptors specific to the
desired cell. Nanocarriers could include liposomes, dendrimers or porous polymeric
nanoparticles. For example, magnetic nanoparticles acting as MRI contrast agents
can be modified to target a specific cell type and can be simultaneously monitored
optically due to addition of optical tags. One indirect adavntage is instrument cost
reduction because if more sensitive structures are used, it is possible to desing appa-
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Figure 1.8: Genomagnetic capture separation [1][35]
ratus with detector and electronic not so advanced. Lasers and optical (for OCT and
NIR) or acoustic (for OAT/PAT) detectors are relatively inexpensive in comparison
to large magnets and X-ray machines.
Another advantage of using optics for imaging is the ability to guide the opti-
cal path with fiber optics, as in endoscopy, enabling internal imaging of vasculature,
deep tissue and possibly the brain. Thermal vibrations produce acoustic waves which
propagate from the underlying tissue to the skin surface. Acoustic detectors on the
surface of the skin pick up the resulting acoustic waves.
One of the most promising nanoparticles type are those made by gold: they can
be used as contrast agents for optoacoustic imaging By controlling shape and struc-
ture, they can be designed to optimally absorb at a desired wavelength. AuNO can
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produce luminescence from lower excitation intensities than typical bioimaging flu-
orophores; that is used with NIR. Gold nanoparticles are also higher photostable
respect to organic fluorophores. Respect to quantum dots, they do not produce sig-
nificant blinking, are easier to fabricate and can be readily modified for biological
specificity and exhibit very low toxicity . All of these characteristics show promise
for gold nanoparticles as an enabling technology to achieve single-molecule in vivo
imaging for early diagnostics [38][39]
Future perspective
As the present, the future of nanoparticles will be focused on the use of pharmaceu-
ticals and drug delivery, although new applications appear on the horizon.
In biosciences, nanoparticles will replace increasingly most part of organic dyes
which require better potstability and a high capability to multiplexing (combination
of more signals into one). There are also concerns developments for direct and re-
mote control of nanoprobe devices; for example the possibility to move the magnetic
nanoparticles to the tumor and to make sure that they reachen the goal: the release
of the drug or locally heating to destroy diseased tissue (hyperthermia). The more
interesting expectation is the development of multifunctional nanomaterials that are
controlled by different types of signals: artificial and external or environmental and
local. [3] [19] [20]
There are two particular fields to take into account for the distant future.
Multifunctional Platforms An area of future impact of nanotechnology for pa-
tient care is the development of in vivo modular, multifunctional platforms to target,
detect and react Dendrimers, due to their highly branched structure, are potential
multifunctional nanostructured platforms. Crosslinking to two or more different types
of nanoparticles could also create a multifunctional platform.
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Therapeutics could be harbored within the dendrimer core or coated onto the
nontargeting nanoparticle enabling targeted drug delivery in conjunction with imaging
for com- bination diagnosis and therapy.
Real-time Monitoring With this techinique it is possible to remotly monitor
patient in real-time. In vivo nanoscale sensors may also provide feedback, based on
physiological status, as part of replacement biological systems, such as an artificial
kidney or pancreas Due to the ultraminiature form factor, identical sensors may be
implanted for redundancy as a safeguard against sensor failure. If an array of these
sensors is used for different targets, it is possible to monitor several parameters of
patient condition simultaneously. [40][41]
Effect on the health of nanostructures
In the previous section, many advantages of nanostructures and in particular of
nanoparticles have been described but these structures could represent negative effects
on human and environmental health because they could be toxic for both.
Few years ago, a search of the negative impacts of plastic in the short and long
term have been approved; in the same way in this year a similar research was started
about compatibility nanostructure with people and environment.
The main fact that contributed to start this research is the size of the nanos-
tructures, which is the same order of magnitude of cells and large proteins; thinking
about the possibility that NPs are facilitated to evade natural defenses of the human
or other species and damaging the cell, resulting cytotoxic.
These studies have to take into account that all living animals have to deal with
nanoscale particles such as those resulting by chemical reactions of the atmosphere,
by pollen, by forest fires or the millions of pollutant nanoparticles that can be felt
during the use of a fire simply.
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Then, there is a division of health impact of nanostructures in industrial and
in biotechnology research. While in industry and in large distribution is taken into
account in particular the impact of these materials on workers during the processing
phase, in biotechnological research it is analyzed the cytotoxicity of each type of
structure and concentration that can lead to effects negative test object.
The general approach of estimation and control of risk comes from identification
of the hazard, which represents the potential of a substance to cause damage. Is also
important the probability of exposure to this hazard and the associated consequences.
The risk is usually controlled by decreasing the probability of exposure and limiting
the release of the material in the air or water.
Rearging the manufacture of nanoparticles and nanotubes, the main determinants
of their toxicity are: their total surface interacts with the organs, the great reactivity
of the surface and the ability to liberate free radicals, their nanometric size that allows
them to penetrate within the organs or cells and the ability to participate or initiate
toxic reactions.
Two main ways in which the nanostructures come into contact with the organs
and with the cells are inhalation and contact with the skin. The small size of the
nanoparticles allows a large part to be able, by inhalation, to be deposited deep in
the lungs. The size of the NP also affects their penetration into cells. In the lungs,
there are localized specialized phagocytes, such as tissue macrophages or leukocytes,
which are able to eliminate large particles. This mechanism has developed mainly in
large animals and humans, to remove potential bacteria or unicellular organisms. But
nanoparticles are able to penetrate directly to the cell membrane with the ability to
interfere with important cellular functions, such as motility and the ability to remove
bacteria. The size of nanoparticles is not the only reason of the possible toxicity, have
great importance also the inhaled quantity and total of surface are. But while the
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toxicity of nanoparticles depends strongly on the amount, the mutagenicity is not so
directly. Stochastically even just a single nanoparticle can create a genetic mutation
that can start tumor formation.
Regarding the inhalation of small amounts of nanoparticles, risks for health are
minimal; instead when the amount becomes high, it is possible to note respiratory
problems, which always depend on the type, size and reactivity of the nanoparti-
cles. Only people at work risk to inhale so large amounts of nanomaterials, but they
can protect themselves by knowing the type of nanoparticle, using appropriate, stor-
ing the NP in liquid suspension rather than powdered, monitoring with sensors the
concentration of NP in air and using other attentions. [4][20]
1.3 Iron oxide Nanoparticles
1.3.1 Introduction
Superparamagnetic nanoparticles of iron oxides have become a major tool for medical
imaging with a lot of applications. This is possible using one or more of properties
that characterized them. There are a lot of kinds of iron oxide nanoparticles: from
just discovered until something already undergoing clinical trials for cancer imaging
applications.
They are also used as diagnostic tool for a vast number of diseases (from atheroma-
tous plaques to degenerative diseases such as multiple sclerosis), hence it appeared of
clinical interest to numerous researchers to investigate the relevance of nanoparticles
in such indications.
It is possible to find applications also in the stem cell field which has attracted a
lot of attention in both neurological and cardiologic research over recent years.
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One of the most interesting research field is the production of contrast agents
for magnetic resonance imaging (MRI). These are iron oxides magnetite (Fe3O4),
maghemite (γFe2O3) or other ferrites that are insoluble in water. Unlike ferromag-
netic substances and because of their size, superparamagnetic agents have no magnetic
properties outside an external magnetic field [42][43]
Superparamagnetic agents are highly effective in MRI as they are strong enhancers
of proton relaxation.
Superparamagnetic nanoparticles are small coated crystals of iron oxides (figure
1.9), characterized by a large magnetic moment in the presence of a static external
magnetic field. This large magnetic moment is caused by a crystal ordering which
induces a cooperativity between the individual paramagnetic ions constituting the
crystal. Consequently, the magnetic moment of superparamagnetic particle is greater
than the sum of each paramagnetic ions constituting the crystal.
Figure 1.9: General structure of iron oxide nanoparticles.
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These small superparamagnetic crystals are smaller than a magnetic domain (ap-
proximately 30 nm) and, consequently, they do not show any magnetic remanence
unlike ferromagnetic materials. The interaction between surrounding protons of wa-
ter molecules and the magnetic moment of superparamagnetic particles results in a
decrease of relexation time (t1 and t2).
The multiple components regulating the efficacy of these agents require them to
be characterized as accurately as possible by information such as the size of the iron
oxide crystals, the charge, the nature of the coating, the hydrodynamic size of the
coated particle, etc. These physicochemical characteristics not only affect the efficacy
of the superparamagnetic particles in MRI, but also their stability, biodistribution,
opsonization and metabolism as well as their clearance from the vascular system.
[44][43]
1.3.2 Properties and Characteristics
Magnetic nanoparticles have different types and different compositions: in most cases
it is an oxide bonded to a metal. Some examples are:
Al2O3, Al(OH)3, B2O3, Bi2O3, CeO2, CoO, Co3O4, CrO3, Cr2O3, CuO, Dy2O3,
Er2O3, Eu2O3, FeO, Fe2O3,Fe3O4, Gd2O3, HfO2, In2O3, La2O3, MgO, Mg(OH)2,
Mn2O3, Mn3O4, MoO3, NiO, Ni2O3, PbO, SiO2, SnO2, Ta2O5, TiO2, ZnO e
ZrO2
Some TEM images are showed in Figure 1.10.
The main applications of these magnetic nanoparticles are: biomaterials, catalysts,
fluids for heat transfer, nanocomposites, the transparent conductive coatings and
optical devices capacitors, semiconductor transistor, materials for optical fibers and
lasers, additives for different types of material, dyes to glass and ceramics for the
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sintering additives and many more. [45]
Figure 1.10: TEM images of different nanoparticles Top left: Al2O3; top right: SiO2;
bottom left: SnO2; bottom right: ZrO2. [45]
Iron Oxide
Particular significant are magnetic nanoparticles formed by iron oxide. Iron oxides
are three: wustite FeO, hematite F2O3 and magnetite F3O4, but only the last two
are used for magnetic nanoparticles production.
The maghemite is an oxide of iron Fe3+, its molecular weight is 159.69 and it is
possible to find it in nature formed by weathering or oxidation at low temperature
starting from magnetite; precisely its name derives from MAGnetite and HEMatite
that shares the composition and the strong magnetism mineral, which is the physical
properties that better characterizes it. The appearance and molecular structure are
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shown in figure 1.11.
Instead, the magnetite is the most high iron content material (about 72.5%) and for
this reason it is widely used in industries dealing with metals. With a large percentage
of iron, it is one of minerals with the more intense magnetic properties existing in
nature. It is a mixture of both oxidation of iron: Fe2+ and Fe3+, its molecular
weight is 231.54 and in nature it can be found in igneous and metamorphic rocks.
Magnetite can be produced biologically by a wide variety of organisms. Appearance
and molecular structure are shown in Figure 1.11.
Figure 1.11: Geology and molecular structure of maghemite (top) and magnetite
(bottom) [46][47]
The synthesis of iron oxide Fe3O4, also called synthetic magnetite, can be prepared
using various processes. One of these is an oxidation of nitrobenzene with an ion of
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iron derived from iron chloride FeCl2:
C6H5NO2 + 9Fe+ 2H2O → C6H5NH2 + Fe3O4 (1.1)
Other two processes are the reduction of maghemite by hydrogen and carbon
monoxide, respectively:
3Fe2O3 +H2 → 2Fe3O4 +H2O (1.2)
3Fe2O3 + CO → 2Fe3O4 + CO2 (1.3)
Although quite simple, the described processes show just the chemical principle
used for synthetize IONP but until know there is not control for size and size distri-
bution of desired nanoparticles. This is only the starting point of their production.
Iron oxides find application in several fields: in the production of ceramics and
glass, also as colorants, in the preparation of cosmetic, to color and increase the
strength of steel and many others. The maghemite nanoparticles are used in the fol-
lowing fields: anti-corrosion agents, catalysts, gas sensors, nonlinear optics, pigments,
semiconductors, and biomedicine. Instead, the applications of the nanoparticles di
magnetite are found in: color imaging, detoxification of biological fluids, absorption
of electromagnetic waves, ferrofluids, magnetic separation of cells, magnetic coatings,
magnetic detectors, coolers, magnetic contrast agents in MRI, magneto-optical de-
vices, semiconductors, toner for printers and biomedicine [46][47][48][49].
Ferrofluid
A particular application of iron oxide nanoparticles is as ferrofluid. A ferrofluid is
a liquid which becomes strongly magnetized in presence of a magnetic field.
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Ferrofluids are colloidal liquids made of nanoscale ferromagnetic, or ferrimagnetic,
particles suspended in a carrier fluid (usually an organic solvent or water). Each
tiny particle is thoroughly coated with a surfactant to inhibit clumping. Large ferro-
magnetic particles can be ripped out of the homogeneous colloidal mixture, forming
a separate clump of magnetic dust when exposed to strong magnetic fields. The
magnetic attraction of nanoparticles is weak enough so that the surfactant’s Van der
Waals force is sufficient to prevent magnetic clumping or agglomeration. Ferrofluids
usually do not retain magnetization in the absence of an externally applied field and
thus are often classified as ”superparamagnets” rather than ferromagnets.
The main application of ferrofluids is the reduction of friction. If applied to the
surface of a very powerful magnet, it can glide on smooth surfaces with minimal
resistance [50]
Production and synthesis
One of the main problems of synthesis of superparamagnetic nanoparticles is the col-
loidal nature of magnetic nanoparticles. Consequently, a full set of analytical methods
should be used in order to characterize the efficacy (in terms of magnetization and
relaxivity) and purity of nanoparticles and the reproducibility of the synthesis pro-
cess. Moreover, the physicochemical and biological behavior of the particles, can be
affecteted by the size, the geometry, the composition of the crystals, the charge of
the particles and the nature of the coating. An accurate description of the physico-
chemical properties of these nanoparticles is crucial. The size of the crystals varies
from agent to agent, but also depends on the measurement technique. The core size is
generally between 4 and 10 nm. The size of the crystals can be appreciated by trans-
mission electronic microscopy (TEM). Moreover, the sample preparation can induce
aggregation of the colloids and the TEM measurements may consequently not reflect
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the crystal size in solution. [43][51][52]
The hydrodynamic size of nanoparticles includes the global size of the particle:
several magnetic crystal surrounded by the coating molecules and the coordinated
water molecules on the surface of coating. It is measured by photon correlation spec-
troscopy (PCS) and dynamic light scattering (DLS). In both tecniques the intensity
of the diffused light is modulated by the Brownian motion of the particles in solution.
The correlation between time and scattering intensity gives information on particle
size in solution. Different mathematical models and weighting parameters are used,
unimodal or multimodal distribution, distribution in number, volume or intensity,
display result giving right size distribution of nanoparticles. The result takes into
account the hydrodynamic radius of structure that greatly depends on the type of
coatings; so it is very difficult to compare different types of MNPs. [53][54][55]
There are two main categories of superparamagnetic agents
• superparamagnetic iron oxides (SPIOs), larger than 50 nm in size;
• ultrasmall superparamagnetic iron oxides (USPIOs), smaller than 50 nm in size.
This difference has significant effects in the ratio of relaxivity constants r1 and r2
but also in plasma half-life and biodistribution.
Other fundamental characteristics of these agents are the nature and charge of the
particle coating. The charge on the surface of the nanoparticles is usually appreciated
by the ζ−potential measurement deduced from the measurement of electrophoretic
mobility. Unfortunately, the value of ζ−potential of superparamagnetic nanoparticles
is rarely described in literature.
So it is possible to affirm that the relationship between the structure, the compo-
sition and the charge of nanoparticles and their potential in terms of efficacy, biodis-
tribution and safety, is not yet well understood and greatly depends on the types of
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metal core and coating used to produce nanoparticles.
So, the synthesis is one of the most important parameters to produce nanoparticles
with precise properties to exploit for applications. For this reason methods for the
synthesis of nanoparticles are manifold, some simpler and some more complex. Each
method will get different results regarding morphology, size, and magnetization. For
all of them it is possible to define these advantages and disadvantages. [3][43]
1. Pyrolysis/aerosols: this technique allows to produce spherical nanoparticles
with a size range between 5 and 60 nm with a very wide distribution, a mag-
netization value between 10 and 50 emu/g with good magnetic properties. The
advantage of this method is the great production of nanoparticles that can be
summarized in a single experiment; in the negative the produced nanoparti-
cles make aggregate too easily. The physical principle of this technique is laser
pyrolysis. Using a laser, specific material is heated and the nanoparticles are
produced from it.
2. Gas deposition: this technique allows to produce spherical nanoparticles with
a range of size between 5 and 50 nm with a narrow distribution; a magnetization
value greater than 20 emu/g. It is a very beneficial method for the deposition of
protective coating or for the production of thin films. The main disadvantage is
that it requires high temperatures for the gas production. The method is based
on an instrument consisting of several chambers; inside these chambers a gas
containing the constituents of the nanoparticles is made to deposit on specific
structures for the production of nanoparticles.
3. Bulk solution: this technique allows to produce spherical nanoparticles aggre-
gates, ranging in size between 10 and 50 nm with a very wide distribution, a
magnetization value between 20 and 50 emu/g, expressing a superparamagnetic
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behavior. It represents a very advantageous method because for each synthesis
a large amount of nanoparticles is produced. One disadvantage is the uncon-
trolled oxidation that may happen to nanoparticles and the appearance of a
diamagnetic contribution of the same. The bulk solution refers just to that part
of the solution where the molecules contained are influenced by other similar
molecules and not from other solid or gaseous molecules. It is a sort of self
assembly.
4. Sol-gel: this technique allows to produce spherical nanoparticles, with high
porosity, ranging in size between 20 and 200 nm with a very wide distribution,
a magnetization value between 10 and 40 emu/g, expressing behaviors param-
agnetic. There are two advantages: the easy selection of the size and the ability
to mix different components for the production of a type of nanoparticles. The
disadvantage is that production of sol-gel matrix can remain bound to the sur-
face of the nanoparticles. The production of nanoparticles is derived indirectly
by the sol-gel method. What has been described as sol-gel is a colloidal suspen-
sion able to solidify forming a gel. Nanoparticles that are synthesized inside the
obtained porous product.
5. Microemulsion: this technique allows to produce nanoparticles cubic or spher-
ical, with the absence of aggregates, with a range of size between 4 and 20 nm
with a very narrow distribution; a magnetization value greater than 30 emu/g,
expressing superparamagnetic behavior. There are two advantages: the great
uniformity of the properties between the produced nanoparticles and easy mod-
ulation of the size of the same. But there are also two disadvantages: surfactants
are difficult to remove and only a small amount of nanoparticles can be produced
at the same time.
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[56][57][58][59][60][61][62]
1.3.3 Specific properties for biomedical applications
Biomedical applications have attracted the most interest in the nanoparticles: con-
trast agents for MRI, drug delivery and hyperthermia. Minor application, you can
consider half way between the drug delivery and magnetic properties, it is handling
by external magnetic field.
MRI contrast agents
The iron oxide and Fe3O4, containing 3 ions of iron, is one of the natural molecules
more paramagnetic. This kind of molecule is able to decrease the relaxation times
of the magnetization vector of the tissues containing them, so as to be mapped on
the image of the diagnostic resonance. So, if nanoparticles can bind with tumor cells,
the tumor region will be more visible than other anatomical zones helping the char-
acterization and facilitating therapeutic practice such as export surgical or radiation
therapy.
Drug delivery
The drug delivery is a process of administration of pharmaceutical components that
has the purpose of producing therapeutic effects in humans or in animals. In these
specific cases, the administered drugs are conveyed together with other molecules
which have multiple purposes. The main tasks of these molecules are: location of the
tissue or areas that require a cure and to facilitate the absorption of the drug by these
areas.
The role of nanoparticles in drug delivery is secondary. Nanoparticles do not have
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a direct healing power of cancer or any other disease, but there are advantages deriving
from two important properties: the large surface reactivity and the nanometric size.
The large surface reactivity of nanoparticles yields the possibility to form bonds
with different types of molecules, as shown in Figure 1.5. The main molecules are:
specialized drug for the treatment of that type of cancer, various biocompatible coat-
ings, different types of ligand, antibodies and other structures.[43]
Various biocompatible coatings play several roles, from simple to more compli-
cated. For example, it is necessary to coat the nanoparticle of iron oxide with a
polymer layer, which may be dextran or poly-ethyleneglycol (PEG), for the simple
reason that the nanoparticle, already coated with oleic acid, is not soluble in pure
water, but only in non-polar solvents (for example toluene).
Nanoparticles coated with polymer (PEG, for example) are soluble in water and
then the suspension coated nanoparticles is more biocompatible than uncoated. There
are more complicated roles for coating molecules: they have to contribute to a total
compatibility and to a specific activation, for example they have to be pH, pCO2 or
pO2 sensitive. They also are resistant to chemical reactions that take place at the
contact with the specific tissues for which they were produced. Then for each type
of application exist a lot of combination between core materials, coatings, activators
and drugs.
Even the ligands, which are bound to external coat, have clear tasks. The main
purpose is communication between the drug delivery carrier and tissue cells. Proper
communication between these two structures can lead to three benefits that are of
great importance to the basic theory of drug delivery mediated by nanoparticles. [20]
1. The regulation of immune response: communicating with the immune cells,
ligands must make sure that this is not completely suppressed. This could
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bring local benefits to developing tumor invalidating the work of the drug, a
drug that has been developed taking into account a normal immune response to
the region affected tissue. The other possibility is that the enhanced immune
response is going to attack the nanoparticles, limiting the strength and action
range.
2. Direct communication with the cell membrane: this type of communication can
modify membrane permeability. This can happen for blood vessel endothelial
so nanoparticles are able to leave the bloodstream and penetrate into tissues
and in the case of the cell membrane of cancer too. So drug, just released from
the MNPs, can enter easier cells into the cytoplasm.
3. Tumore targeting: making oncology analysis on the tumor it is possible to
determine which proteins exposes the tumor cell on its surface. So once produced
a type of nanoparticle that has this specific ligand entrapped in the polymer
coatings, it will accumulate only close to tumor, limiting the dose to healthy
cells and reducing the quantity of a drug required for tumor therapy.
Independently for which tumor tissue the particle is designed, the nanoparticle
solution will be injected intravenously to the patient; then the first interaction of
the nanoparticles and their coatings will be with the blood, in second place with
the immune system. Thanks to the polymer coatings, it is possible to increase the
stability of the structure, the half-lives of nanocarriers within the bloodstream and
the duration of entrapment of the drug.
As the reactivity to surface, but also the size of the nanoparticles have a con-
siderable importance with regard to drug delivery and in the same way also for the
magnetic resonance imaging and hyperthermia, because the effectiveness of these two
practices, a diagnostic and a therapeutic, depend heavily on the amount of magnetic
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material content, hence on the size. [20]
Opsonization, which is the mechanism of coating of the external structure by the
body, and the size determine the fate of the NP after the intravenous injection. This
depends on the two organs filter our body: the venous sinuses of the spleen tend to
eliminate particles larger than 200 nm and the liver removes large particles from the
bloodstream. Therefore, since the half-life of life of MNPs decreases with increasing
their size, the choice of the size of the NP depends on several parameters. In a healthy
tissue the size of the pores of the endothelial tissue is about 10 nm, while in tumor
tissue ranging from 200 nm to 1200 nm, depending on the type of tumor. Also in
healthy tissue: particles much larger than 10 nm are eliminated by phagocytosis,
particles slightly larger than 10 nm are eliminated by pinocytosis, a process similar
to phagocytosis.
A structuring increasingly complex of the coatings can lead to a problem: the
longevity and the ability of the mimetic MNPs compared to the immune system are
in contrast with the presence on the surface of functionalities that allows targeted
action. This can be translated as increasing number of coating layers it is possible to
decrease the specificity of the nanoparticles, such as their ability to perform tasks.
The first of the two possible solutions is based on the EPR effect (Enhanced Perme-
ation and Retention effect): this effect is caused by cancer cells that alter the porosity
of the close capillaries, destroying their filtering mechanisms. Therefore, taking ac-
count of this, we can limit the number of selected ligands to facilitate nanoparticles
to leave blood stream and penetrate tumor tissues. [3]
The second solution is based on the use of viruses: genetically modified virus are
exploited to avoid the immune response. Although this implies the risk of unexpected
behavior of the viruses that could not avoid the immune response, but make it even
stronger.
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A further possible solution consists in the synthesis of biological membranes that
contain nanoparticles that may be free or bound to these structures. Some examples
of these cages are biological: the liposomes, the lipid-based nanocapsules, the cages
protein, the polymeric micelles and the cages of hydrogel.
Taking into account that liposomes are drug delivery carrier more used in clinical
pratice in last years, is interesting to compare them with polymer coatings. It easy
to note three advantages of coatings polymer:
1. better control of the properties of the coating determine the longevity in vivo
and thickness, then the volume necessary to trap the drug;
2. a selection of the polymer formulations compatible with the chemistry of drug
molecules to facilitate the entrapment;
3. the design with specific properties sensitive to the pH or temperature, for the
localized release of drugs.
However, they also have negative aspects: they induce easily the inflammatory re-
sponse and accumulation of proteins on their surface.
Then, as happens in many similar cases, there is not a compartimentation of
always suitable nanoparticles, but it depends on specific cases.
Hyperthermia
Hyperthermia is a kind of therapy performed by heat. The care of patients with
hyperthermia is based on two facts: the first goes back nearly 50 years ago when some
studies have shown that tumor cells grown in the laboratory survive less than normal
cells, when the temperature increases. Switching from regular 37C to 42-43C, there is
a significant die-off of cancer cells. The second is that drugs and radiation, which are
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the bases of chemotherapy and radiotherapy, have demonstrated their effectiveness
issues from biochemical reactions inside the cell. These chemical reactions, such as
all chemical reactions, are influenced by heat.
In physiological or pathological condition if the temperature of a cell is increased
from 37C to 42C the action of these substances or these physical agents, such as
radiation, is facilitated. Thus there is the first effect of hyperthermia which is an
indirect effect of destruction of tumor cells; the second effect facilitates the action of
drugs and radiation and the third effect is the simulation of immunity of the subject.
So hyperthermia can have a significant role in cancer therapy, given also the fact that
collateral effects are limited and low intensity.
The effect of hyperthermia can be locally obtained with magnetic fluids. These
fluids, used in biomedical applications, are colloids containing magnetic nanoparticles
to single domain dispersed in an organic matrix. Magnetic nanoparticles, with a size
less than 50 nm (critical diameter), adopt a configuration with a single domain and
superparamagnetic behavior. In addition, since they do not aggregate, it is possible
to consider them as a system that do not interact.
In medicine, the magnetic hyperthermia uses the magnetic fluids to heat the tumor
tissue in an uniform, targeted and effective manner applying an external magnetic field
with a frequency between 100 and 500 kHz and amplitude of the order of kA/m.
The heating of the particles is primarily by the effect of relaxation processes:
Brown and Neel. The relaxation of Brown is linked to the rotation of the particle in
the fluid in which it is immersed and, in this case, the heat is produced by friction.
While, in the relaxation of Neel there is a rotation of the magnetic moment and then
the production of eddy currents that heat the tissue. The effectiveness of treatment
is evaluated in terms of heat transmitted to the tumor tissue.
In vitro, the transmitted energy is related to the size and concentration of nanopar-
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ticles and to the characteristics of applied magnetic field (frequency and amplitude).
In vivo should be taken into account the effect of heat dissipation due to blood per-
fusion which can reduce the effective heating. [3] [19]
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Chapter 2
The Nanosmart Project
Taking into account the large amount of information about technology and nanotech-
nology described in the first chapter of this thesis, University of Trento in collaboration
with many international research centers has developed the Nanosmart project. The
goals of this project are the study, preparation and experimental verification of iron
oxide nanoparticles carriers for tumor diagnosis and therapy. They have been designed
for diagnosis as contrast agents for magnetic resonance imaging and for therapy as
drug delivery and hyperthermia carriers.
The scheme illustrated in Figure 2.1 describes the iron oxide nanoparticle pathway
from injection to drug release inside the tumoral cells.
This was and continues to be a huge and innovative project. It has been written
five years ago by six research center all over the world: Biotech - University of Trento,
CNR-IBF (Trento), GeorgiaTech (Atlanta, USA), CNRS-U.M. (Montpellier, France),
FBK-IRST (Trento), CNR-IFN (Trento) and Ludwig Boltzamm Institute for Cancer
(Wien, Austria).
The project started 4 years ago and to be able to design a innovative carrier and
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Figure 2.1: Scheme of pathway of MNPs after injection in blood stream [63]
eventually new commercial products it was very important to update our knowledge
about nanotechnology, considering the information available in literature and the news
for commercial nanoparticle products.
2.1 State-of-art of commercial nanoparticles
It is easy to get lost inside the literature about magnetic nanoparticles; there are
many papers, books and works about this topic. The first works are more then 30
years old and at the same time a lot of new structure are discovered everyday. To
obtain a good report about this research field it is useful to focus on nanoparticles
ready to be investigated in clinical trials.
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As time goes by some parts of this project are still underdeveloped and others
were abandoned for many reason but this is not important because the idea was not
to copy the structure but only to cross useful information about size, coating, drug
entrapment and ligands to transfer to our iron oxide nanoparticles. [64]
The most interesting iron oxide nanoparticles are:
• Feridex, also called Ferumoxide and Endorem, is a sterile aqueous colloid of
superparamagnetic iron oxide associated with dextran for intravenous admin-
istration as a MRI contrast medium for the detection of liver lesions that are
associated with an alteration in the RES. Feridex is taken up by macrophages,
found only in healthy liver cells but not in most tumors. Tissues such as metas-
tases, primary liver cancer, cysts and various benign tumors, adenomas and
hyperplasia retain their native signal intensity, so the contrast between normal
and abnormal tissue is increased. Feridex is a black to reddish-brown aqueous
colloid. In November 2008, AMAG Pharmaceuticals, Inc. decided to discon-
tinue the manufacturing of Feridex.
• Sinerem, also Combidex is an ultrasmall superparamagnetic iron oxide (US-
PIO) to detect metastatic disease in lymph nodes. Metastatic nodes show less
uptake of this MRI contrast agent, which results in less signal decrease and
allows the differentiation of normal lymph nodes from normal-sized, metastatic
nodes. Lymph node imaging with Sinerem is performed 24 to 36 hours after
slow infusion. Normal lymph nodes turn black post contrast, namely on T2*
weighted images. Metastatic lymph nodes remain unchanged in signal intensity.
Indication and Diseases: Cancer, Imaging for diagnosis, Lymphatic disorders.
Guerbet decided in 2007 to withdraw its Marketing Authorisation Application
(MAA) for Sinerem.
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• Lumirem belongs to the negative oral contrast agents (same as GastroMARK).
It used to distinguish the loops of the bowel from other abdominal structures
and physiology. When Lumirem is ingested, it flows through and darkens the
stomach and the small intestine in 30 to 45 minutes. By more clearly identify-
ing the intestinal loops, Lumirem improves visualization of adjacent abdominal
tissues such as the pancreas. Additionally, in Europe Lumirem is approved for
rectal administration to delineate the lower intestinal system.
• Resovist is an organ-specific MRI contrast agent, used for the detection and
characterization of especially small focal liver lesions. Resovist consists of su-
perparamagnetic iron oxide (SPIO) nanoparticles coated with carboxydextran,
which are accumulated by phagocytosis in cells of the reticuloendothelial system
(RES) of the liver. The uptake of Resovist Injection in the reticuloendothelial
cells results in a decrease of the signal intensity of normal liver parenchyma on
both T2- and T1 weighted images. Most malignant liver tumors do not contain
RES cells and therefore do not uptake the iron particles. The resulting imaging
effect is an improved contrast between the tumor (bright) and the surrounding
tissue (dark). Resovist can be injected as an intravenous bolus, which allows
immediate imaging of the liver and reduces the overall examination time. A
dynamic imaging strategy after bolus injection supports to characterize lesions.
In comprehensive clinical trials, it demonstrated an excellent safety profile. In
2001, Resovist was approved for the European market. Resovist competed with
Primovist, the other liver imaging agent of Bayer Schering Pharma AG. Due to
this reason, the production of Resovist has been abandoned in 2009.
• Clariscan is an iron-based contrast agent with large molecular size, which
prevents diffusion into body tissues and will be developed for MR imaging of
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the liver (taken up by macrophages), tumor microvasculature and microvessel
permeability. The blood half live of the particles with 11-20 nm diameter is 3-4
hours. At this time the development of Clariscan is discontinued.
• Abdoscan is a superparamagnetic oral contrast agent consists of large iron
oxide particles, coated with insoluble material. Abdoscan particles have a mean
diameter no less than 300 nm. Gastrointestinal superparamagnetic contrast
agents are used for negative bowel enhancement. Abdoscan was approved in
Europe but was taken off the market in 2000, and all sales stopped by the end
of 2002.
• VSOP-C184 means very small superparamagnetic iron oxide particles. This
new class of contrast agents with smaller particle size than SPIO offers advan-
tages for MR angiography. SPIO particles are usually coated with an organic
polymer such as dextran, carboxydextran or polyethylene glycol, which limits
the minimal overall particle size that can be obtained. VSOP-C184 consists
of an aqueous solution of superparamagnetic iron oxide particles with a citrate
coating and the overall particle size of 4-8 nm.
2.1.1 Interaction lived tissue and application
After the injection the first interaction of nanoparticles is with blood stream. In par-
ticular iron oxide nanoparticles are internalized into macrophages (Fig. 2.2) and other
phagocytic cells. Every interaction of NP depends on a lot of variables: one of the
most important is size. Size can strongly interfere with their capacity to be internal-
ized into macrophages or other phagocytic cells following intravenous administration.
Studies on different types of NP (sinerem) show different properties. NPs that have a
hydrodynamic diameter very similar to iron oxide MNPs used in this work (15-30 nm)
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show a long blood residence time, which allows them to easily access macrophages
located in deep and pathologic tissues (such as lymph nodes, kidney, brain, osteoar-
ticular tissues, etc.). This is very positive because it is difficult to access these organs
respect to other organs.
Figure 2.2: Intracellular localization of MNPs following a 24-h incubation with human
monocytes. Iron staining with Prussian blue and counterstaining with eosin [65]
Iron oxide nanoparticles with a very small size such as resovist have a higher
macrophage uptake; the effect of this is a faster blood clearance and, consequently,
a more limited access time to the deep compartments. For example, the elimination
half-life of VSOP-C184 in healthy volunteers is only 0.5-1.5 h after bolus injection
Conversely, pegylated Clariscan 1 because of the pegylation of the coating starch, can
be regarded as ”stealth nanoparticles” which are hardly recognized by the macrophage
and probably not suitable for macrophage imaging, but they shows a long blood
residence time.
Not only the size is important for tissue interaction, but also the superficial
2.1. STATE-OF-ART OF COMMERCIAL NANOPARTICLES 63
chemestry. It has recently been shown that superparamagnetic nanoparticles with
an amino-functionalized PVA coating can interact with human melanoma cells with-
out any cytotoxicity. This interaction of the nanoparticles with melanoma cells was
found to be active, energy-dependent and saturable [66]. The increase of uptake in
the presence of amino groups is consistent with the well-known uptake of cationic
liposomes, mainly for transfection purposes.
A recent study compared anionic nanoparticles coated with hydrodynamic diam-
eter 24 nm with ferumoxtran-10. In vitro ferumoxtran-10 enter easier the human
prostatic adenocarcinoma cells than with ferumoxtran-10. According to their nega-
tive charged and hydrophilic coating, nanoparticles show different degrees of uptake
by macrophage-like cells. The macrophage is a specialized host defense cell with en-
docytic properties. They are involved in a lot of diseases; for this reasons they are
one of the most used pharmaceutical target. Apart from particle size, the phagocytic
uptake is dependent on the surface properties of the nanoparticles; ionic carboxy-
dextran coating NP enter easier the phagocyte easier than nonionic dextran coating
NP .
Other studies show that the value of charge of coating gives to NP specific prop-
erties: the negative charged coating is more biocompatible, instead the positive one
has a better interaction with cell membrane.[67]
2.1.2 Pharmacokinetics
To better design NP it is very important to understand the typical velocity of pro-
cess that characterizes NP in vivo. Knowing this parameters is useful to prepare
nanoparticles with specific amount of drug and particular drug release speed.
For example, Ferumoxtran-10 is completely degraded in the macrophage lysoso-
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mal compartment within 7 days , and plasma elimination half-life is strongly species
dependent: 2 hours in rats, 6 h in rabbits and 24-36 hours in human after intravenous
injection In both rats and rabbits, increasing the dose it is possible to have longer
half-life because there is a saturation of uptake by liver and spleen.
Taking into account that the diffusion of NP in tissue strongly depends on blood
residence time, animal imaging experiments are generally performed using high doses
of nanoparticles of 200-1000 mmolkg−1, while for human experiments the used dose
is about 45 mmolkg−1.
An unexpected parameter to characterize the uptake process is the patient age. In
case of rats, after a injection of VSOP-C43, younger animals show a blood resistance
value less than 50% respect to old animals. This fact suggests a higher macrophage
uptake in younger animals.
The iron derived from the uptake of iron oxide nanoparticles is bioavailable and is
incorporated into the normal body iron pools, such as hemoglobin This is also showed
by the increment of ferritin levels inside the body Ferritin is a ubiquitous intracel-
lular protein that stores iron and releases it in a controlled fashion. An example is
dextran-coated iron oxide nanoparticles which are degraded by Kupffer cells (special-
ized macrophages located in the liver) to incorporate most of the iron they contain into
ferritin and/or hemosiderin (when the intracellular concentration of ferritin becomes
relatively high) before exocytosis. [68][69][70]
A use of Ferumoxtran-10 would be the detection of nodal metastases. After in-
travenous infusion, USPIO nanoparticles are distributed to the lymph nodes by two
distinct pathways:
• direct transcapillary passage through venules into the medullary sinuses of the
lymph node, followed by phagocytosis by macrophages
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• non selective endothelial transcytosis into the interstitial space in the body, fol-
lowed by uptake of the nanoparticles by draining lymphatic vessels and transport
to the lymph nodes via afferent lymphatic channels
There are several methods to administrate iron oxide nanoparticles: slow intra-
venous infusion (Endorem 1 /Feridex 1), injected as a bolus (Resovist 1) and sub-
cutaneous injections (ferumoxtran-10) Each of these possibilities has advantages and
disadvantages depending on the NP type and on application. [71][72][73]
2.2 Nanosmart Project
Nanoparticles used for Nanosmart Project are designed, set up and produced accord-
ing to the information described in the previous section of this chapter.
The ultimate structure includes:
• NP core: it is magnetite maghemite mixture produced by a thermo-decomposition
of iron complex in a mixture of oleic acid and oleylamine. Both of them are
strongly bound with the core and will be alway present in final composition of
nanoparticle.
• NP coating: it is made using a amphiphilic molecules; it is a phospholipid
attached to a polymer chain (PEG). This molecules can interact with oleic acid
and oleylamine and form a hydrophilic external shell with polyethylene glycol.
• NP functionalization:
– Labeling: iron oxide nanoparticles are magnetic properties but do not have
fluorescent characteristics. DiI fluorescent dye is used to become fluores-
cent the NP. This dye is hydrophobic and can be entrapped inside the
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hydrophobic double layer formed by oleic acid and the fatty acid of phos-
pholipids with PEG.
– Targeting: a epidermal growth factor recepetor (EGFr) antibody is at-
tached on the external shell of NP. This antibody can interact with the
EGFr of tumoral cells to increase uptake of nanoparticles.
• NP drug loading: the main application of this NP is drug delivery. Dox-
orubicin is the choose drug to delivered togheter with nanoparticles. It is very
famous cancer chemotherapy. This drug has a particular behavior in solution:
indeed, it is pH sensitive. At low values of pH (4-6) it is hydrophilic, at high
values (7-8) hydrophobic. It is possible to exploit this characteristic as release
mechanism. The drug enters the hydrophobic layer of NPs when they are sus-
pended in basic solution and it can exit in acid solution, for example inside the
lysosome (pH is about 4)
In the following chapter ideas, methods and protocols to obtain this type of











Main protocols, tests and results to verify the ideas and to keep the promise described
in the previous chapter will be shown in this part. As often happens, ideas are very
simple and clear, but their application is not so easy. The better fulfillment is a
long pathway between failures, renounces and modification, but all problems could
represent a new starting point for better discoveries and applications.
For that reason, the experimental approach for this work followed the philosophy
of “step by step” and “trial and errors”.
The entire work was dived in different four tasks; the most relevant are: production
of MNP, their functionalization, in vitro and in vivo tests. Easy to understand that
it is impossible to deal oddly with these parts: functionalization depends on used
production methods, results of in vitro tests depend on nanoparticle functionalization
and so on.
For each of the four mentioned steps purposes, materials, protocols and results
will be illustrated in the next chapters.
At the beginning, the most difficult decision was the choice of the material for
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nanoparticles production. During these years even four different types of MNP have
been taken into account to carry out the project:
• iron oxide nanoparticles produced at the University of Trento (Italy),
called UNITN-MNP;
• iron oxide nanoparticles produced at GeorgiaTech of Atlanta (US),
called GATECH-MNP;
• iron oxide nanoparticles produced at the University of Montpellier (France),
called FRANCE-MNP;
• gold nanoparticles produced by FBK-IRST of Trento (Italy),
called AuNP.
This thesis focuses only on UNITN-MNP and GATECH-MNP, describing work
and results pertaining to them. Indeed, it is interesting to understand the synthesis
process of UNITN group, while GATECH-MNP resulted the best and more suitable
for our purposes.
To do this chapter more readable, materials, reagents and instruments used in
chapter are described in section 5.4
Chapter 4
UNITN MNPs
4.1 MNP Synthesis and chemical-physical charac-
teristics
This type of magnetic nanoparticles has been developed at the BIOtech research center
of University of Trento. The synthesis protocol was based on microemulsion: highly
monodispersed iron oxide nanoparticles were synthesized by using the aqueous core
of aerosol-OT (AOT)/n-Hexane reverse micelles in N atmosphere. Reverse micelles
have an aqueous inner core, which can dissolve hydrophilic compounds, salts, etc.
A deoxygenated aqueous solution of ferric and ferrous salts (molar ratio 2:1, 1 M)
was dissolved in the aqueous core of the reverse micelles formed by 0.05M AOT in
n-hexane. Chemical precipitation was achieved by using a 1 M deoxygenated solution
of sodium hydroxide. The reaction was carried out in nitrogen atmosphere at low
temperature (4◦C) with vigorous stirring. Hexane was evaporated and the particles
were recovered by precipitation in an excess of an acetone-methanol mixture (9:1
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ratio), followed by dialysis using 12-kD cutoff dialysis membrane against double-
distilled water to remove unreacted iron salts. This solution was dried in an oven at
80◦ C and nanoparticles were suspended in toluene. [74].
MNPs, formed inside reverse micelle, have a hydrophobic surface; therefore they
can be suspended only in a non-polar solvent like toluene. Moreover, these MNPs
have high stability (several months). The shape of this NP is ellipsoidal with some
little defects.
4.1.1 Nanoparticle size measurement using DLS and TEM
In this experimental part, characterization and analysis were performed using trans-
mission electron microscope (TEM) and dynamic light scattering (DLS). [51][52][53][54]
As regards TEM analysis, images were produced using the protocol based on the
deposition of a drop of suspension of MNP on a carbon-film coated cupper grid.
Figure 4.1 represents a series of TEM images: a direct, a doubly magnified and a
detail of the latter.
Figure 4.1: TEM images of iron oxide cores produces by UNITN group. Top left:
direct image; right: magnified image twice. Below: detail of an isolated nanoparticle
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Produced nanoparticles have an ellipsoid shape with diameter ranging between 9
and 21 nm, approximately.
Via TEM instrumentation was also carried out the microanalysis, in order to de-
termine which elements compose the sample. Figure 4.2-left represents the frequency
spectrum of the elements analyzed in microanalysis.
Figure 4.2: Left: Energy spectrum by microanalysis of a sample of synthesized MNP.
Right: DLS analysis of iron oxide cores
The graph shows two very high peaks which represent carbon and copper. These
two elements are present because they are the basic constituents of the grid: the
support and coating. The other peaks represent the iron and oxygen which are the
constituents of the iron oxide, components of nanoparticles.
As regards DSL analysis, figure 4.2-right represents size distribution and the av-
erage diameter of nanoparticles.
Produced nanoparticles have an average diameter of about 15 nm, with a very
wide distribution.
The TEM and DLS comparison reveals a large discrepancy of measured dimensions
and shape. This difference follows from the capability of TEM to analyze only one
particle at a time and the ellipsoidal shape of nanoparticles is easily observable, while
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DLS results take into account the whole sample analyzed.
To fill this discrepancy there is the fact that the diameter measured by DLS results
to be 15 nm, which is a value similar to the average between the greater diameter (21
nm) and the smaller diameter (9 nm) measured by TEM.
4.1.2 X-ray photoelectron spectroscopy XPS
All XPS analysis has been performed by Ph.D. Luca Minati at the FBK-IRST (Trento).
The XPS analysis of the MNP synthesized by UniTN show the presence of different
kinds of contaminants. In addition to carbon (285 eV) oxygen (530 eV) and iron (710
eV), XPS also chlorine (200 eV) and sulphur signals are detected. The former is
probably due to a non total reduction of the precursor while the latter derives from
surfactant residuals (sodium bis(2-ethyl-1-hexyl)sulphosuccinate).
The fit of the C1s core line in the following figure shows a principal component
at 285.0 eV associated to hydrocarbon chains. Higher spectra power is found in the
regions 286 - 287 eV and 289-290eV associated to C-O, C=O and carboxylic bonds,
respectively.
As for C1s, also the O1s core line is rather different from that of the previous
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sample. Now the main component (at 532eV) is associated to C-O bonds whole that,
corresponding to the iron oxide (530eV), has a pretty lower intensity. The remaining
components are: carboxylic species at 533eV, at 534eV carboxylic bonds near SO3-
and finally the component at 536 eV is associated to water residuals.
The Fe2p core line is quite different respect to the previous sample due to the
presence of iron chloride. Each of the two peaks of the spin-orbit doublet can resolved
in tow components deriving from Fe oxide and Fe chloride.
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Chapter 5
GATECH MNPs
According to ideas described in chapter 2, also GATECH MNPs have a great potential
as MRI contrast agent for molecular imaging thanks to their excellent T2 relaxivity
and as drug delivery carrier considering their small size and high reactivity. However,
it is necessary to modulate SPIOs to obtain optimal size, T2 relaxivity and surface
functionality for specific applications.
The major part of the work has been done on these MNPs. They have followed a
precise pathway from the first step of synthesis until the last in vivo results.
All experiments and results, good and bad ones, led to reach ultimate development
described in section 2.2.
5.1 Synthesis and coating
Iron oxide cores were synthesized by thermo-decomposition of iron complex in a mix-
ture of oleic acid and oleylamine. These nanoparticles have an external shell of oleic
acid, which makes them to be suspended in toluene, limiting any possible biological
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study. [16][17][75][76][77]
In figure 5.1 there are a graph of size distribution and a TEM image of bare NP
as prepared by Atlanta lab.
Figure 5.1: Left: Size distribution of bare MNP in toluene; Right: TEM image of
same MNP
To make water soluble SPIO, iron oxide cores were coated with 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-X] (DSPE-mPEG
X) using a solvent exchange method. X is the molecular weight of methoxy (polyethy-
lene glycol) ranging from 550 to 5000 (figure 5.2).
Figure 5.2: Chemical structure of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy (polyethylene glycol)-2000
These molecules have polar head (hydrophilic) and non-polar tail (hydrophobic).
This polymer is not toxic and is water soluble and biocompatible. There are different
types of polyethilene glycol, classified by molecular weight and number of monomers.
5.1. SYNTHESIS AND COATING 81
Structures with different length have different physical properties (viscosity) and dif-
ferent applications, meanwhile the chemical characteristic is constant.
In this work, for the majority of cases core size and polymer coating used are:
• 6.5 nm core produced by GeorgiaTech group
• DSPE-mPEG2000 and composed by 43 monomers prepared by Avanti Polar
Lipids Inc.
The coating protocol is the following: the GATECH iron oxide cores were dispersed
in toluene and were insoluble in water prior to modification. A solution of DSPE-
mPEG (4.8 ml at 5 mg/ml) is prepared in chloroform. MNPs in toluene (3 ml at 1
mg/ml) were added in this solution (fig. 5.3). The Iron-PEG ratio in weight is about
1:8.
Figure 5.3: Pictures of argon-flow (left) and rotovapor (right) apparatus to coated
iron oxide core with dried film.
This mixture was then dried under argon gas and left in a vacuum desiccator for
48 h to remove all traces of organic solvents. The dried film was easily resuspended in
deionized water with agitation. In this way, the PEG-MNPs were dispersed in water.
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This protocol has been developed because another dried film technique using a
rotovapor showed worse result. The main difference is the use of vacuum pump to
eliminate toluene and chloroform instead our argon flow.
With both techniques, the obtained film is dried more in a desiccator connected
with a vacuum pump for 16 hours and then MNPs are suspended in water using
ultrasonification.
After this procedure, the solution is composed by:
• Coated nanoparticles (figure 5.4-right)
• Multicore nanoparticles
• Empty PEG micelle (figure 5.4-left)
• Free PEG molecules
• Aggregates.
Coated MNPs are the right structure to obtain. During the coating process and
water re-suspension, it is possible to have unwanted products. In multicore NP dif-
ferent cores are coated by the same polymer shell. The size of this structure is larger
than the required NP size. It is possible to obtain empty micelles too, where PEG
chains in solution can react between them with hydrophilic heads outside and hy-
drophobic part inside. This free chain is the most dangerous structure for stability of
correct MNP.
Moreover, it easy to find PEG free chains and other bigger aggregates so a purifi-
cation processes has been developed of this multi-component suspension . The tree
main steps are:
• centrifugation with specific filter tube (100 kDa) to eliminate free chain
5.1. SYNTHESIS AND COATING 83
Figure 5.4: Left: structure of an empty micelle; Right: structure of PEG coated
MNP
• ultracentrifugation (upper than 40000 rpm) to concentrate correct MNP and
eliminate empty micelle
• 0,22 um filtration to eliminate aggregates.
It is possible to characterize bare MNP (non coated and in toluene) and coated
MNP using dynamic light scattering (DLS) to evaluate size distribution. Figure
5.5-left shows the size distribution using both dried film methods: argon flow and
rotovapor. The argon-flow MNPs have a sharp peak at 24 nm and a small peak around
90 nm. The 80% of MNPs has an average size of 24 nm. Rotovapor MNP have 2 high
peaks at 59 and 130 nm. Comparing these distributions it possible to notice that the
argon-flow protocol is much better than the rotovapor method. Taking into account
that the objective of our project is the synthesis of 50 nm iron compound, argon-flow
MNPs follow completely the specific requests. Using specific polymer-contrast resin
for TEM, in figure (5.5-right), it is possible to assess PEG-MNPs size is around 30
nm.
For this type of nanoparticles there are advantages and disadvantages.
One of these disadvantages is the difficulty to bind polyelectrolytes with the chains
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Figure 5.5: Left: comparison of argon-flow and rotovapor size distribution using DLS.
Right: TEM image of coated MNP using specific polymer contrast resin
of PEG. Indeed, the structure described in figure 5.4-left is complete. There is a core,
a hydrophobic double layer and a hydrophobic external layer and it is very difficult
to add some other layers. However, using specific commercial molecules, it is possible
to select the chemical group for MNP functionalization, for example COOH and NH2
group that are used in several reaction to bind many types of molecules on the surface
of MNP: antibody, dye, proteins and so on. Hence this disadvantage turns out to be
an advantage.
5.1.1 Nanoparticle size measurement using DLS
Dynamic light scattering (DLS) measurement of 6.5 nm iron oxide core indicates that
nanocrystals are well dispersed in toluene with an average hydrodynamic diameter
of 8.12 nm (figure 5.6-left). Coated MNPs with dried film method show different
diameter reliant on type of solution which they are suspended in. [53][54]
In water their average diameter is about 27.8 nm, while for DMSO solution this
value reaches 34.6 nm. These results indicate that iron oxide nanocrystals are stabi-
lized by DSPE-mPEG in DMSO and water.
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Figure 5.6: Left: DLS peaks of iron oxide core and coated MNP in DMSO and water.
Right: DLS analysis of 4 different samples prepared in the same way
MIONs are slightly larger in DMSO than in water. This is presumably due to
the increased solubility of DSPE-mPEG in DMSO so that the coating layer is more
extended.
There is one more thing to take into account for coating process: it is very difficult
to reproduce perfectly the entire process. In figure 5.6-right it is possible to notice
4 different peaks for 4 different batches of coated nanoparticles produced with same
parameters. Measured diameter ranges from 18 to 28 nm.
One of the most annoying parameter during this process is humidity because it can
interact with the size of DPSE-mPEG layer around the core. And it is very difficult
to control humidity during the process, so it is easy to find this little differences of
diameter durign measure.
For simplicity, these MNPs are also called PEG-MNPs.
5.1.2 Nanoparticle size measurement using TEM
Transmission electron microscopy (TEM) was used to determine the size of coated
and uncoated MIONs with core diameters of 6.5nm and 17 nm. [51][52]
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Empty micelles were separated from micellar nanoparticles by ultracentrifuga-
tion. 5 µl nanoparticles solutions was dropped onto a carbon coated copper grid and
negatively stained with 1% phosphotungstic acid. The following TEM images were
recorded with a JEOL JEM-1210 transmission electron microscope connected to a
CCD camera.
5.1.3 Nanoparticle size measurement using AFM
Also atomic force microscope AFM was used to determine nanoparticles size. [78][79][80]
A small amount of PEG-MNPs was dropped on a sheet of mica; after a long drying
in N atmosphere the sample was ready for measurement.
The following two figures clearly show the presence of MNPs on the substrate
surface. The analysis of the roughness leads to an average dimension of 20-30nm.
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So it is possible to measure the size distribution of MNPs with AFM too, but this
technique was abandoned because it is very complex respect to DLS or TEM.
5.1.4 Change of coating recipe
Until now the coated MNP have been produced using only one type of phospholipids
with PEG, but there are different structures of these. One of the most important
difference concerns the functional group attached at the end of PEG polymer chain.
The first MNPs have been coated using DSPE-mPEG that ends with a methoxy
group; it is a not reactive group.
For many purposes it is a good idea to use different chemical groups such as
carboxyl COOH, amine NH2, malemide and many more. These groups are illustrated
in the following image.
88 CHAPTER 5. GATECH MNPS
These groups are very reactive and using specific crosslinker it is possible to exploit
them to bind several molecules on the surface of nanoparticles. In the same way it is
possible to change easily the total charge of the structure. For example, a MNP coated
with DSPE-PEG-COOH is more negative respect to DSPE-mPEG MNP which it is
more negative respect to DSPE-PEG-NH2 nanoparticles.
The most part of described analysis is done using nanoparticles coated with 95% of
DSPE-mPEG and 5% of DSPE-PEG-NH2, called NH2-PEG-MNPs or simply PEG-
MNPs, the reason of this choice will be explained in next sections of this work.
Also the length of the polymer is a variable parameter. In this work DSPE-mPEG-
2000 and DSPE-PEG-NH2-2000 are always used to coat iron oxide core. MNPs with
different length of PEG have been tested, only for coating protocol verification.
As showed in figure 5.7, DLS points out different size distributions of MNP coated
with 350, 2000 e 5000 kDA PEG using a Iron/PEG ratio of 1:8
It is possible to notice that PEG-5000 have same size distribution of PEG-2000
just shifted to the right of 5-8 nm. Instead, the size distribution of PEG-350 is very
bad. Probably the ratio 1:8 is not the right one for this kind of molecules and it is
possible to find multicore NP and aggregates.
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Figure 5.7: DLS analysis of coated MNP usind PEG with different lenght
5.1.5 Change of coating protocol
During the work, a large amount of nanoparticles has been developed. Synthesis
process is expensive because a lot of reagents, tools and instruments are used. The
most expensive reagent is DSPE-mPEG because is a very particular molecule and
it is not so diffuse in industrial. The process ratio used between iron of core and
DSPE-mPEG was 1:8. At the beginning of our research this ratio has been the first
one to show good results for coating of MNP. Indeed, the number of phospholidips
with PEG has to be always larger than NP number because otherwise it is possible
to have multicore NP or aggregates.
Since, unfortunately, this ratio makes MNP very expensive, another ratio has been
tested: Iron:PEG=1:4. This permits to save half quantity of DSPE-mPEG.
In figure 5.8 it is possible to notice two synthesis batches (B1 and B2) produced
at different times.
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Figure 5.8: DLS analysis of 2 different samples: “B1 - vol” are MNP produced form
the first batch maintaining constant volume, ‘B1 - conc” are MNP produced main-
taining constant concentration, ‘B2 - vol” are MNP produced form the second batch
maintaining constant volume, ‘B2 - conc” are MNP produced maintaining constant
concentration and “Ratio 1:8” are MNP produced with with the previous ratio be-
tween iron and PEG
In the same batch, two conditions have been tested:
• Same concentration: thereby half volume. There is a half quantity of solution
respect to 1:8 ratio.
• Same volume: thereby half concentration. There is a half value of concentra-
tion respect to 1:8 ratio.
DLS analysis illustrates that there are not big differences between different meth-
ods, in case of constant volume or concentration, and between different ratios.
So using the coating dried film method based on argon flow it is possible to obtain
a very good size distribution using a ratio 1:4, instead of more expensive 1:8.
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5.1.6 Protocol for the determination of Fe concentration
To know directly the right number of nanoparticles in solution or uptaken by cells is
very difficult. One way to achieve this target is to measure the amount of iron ions
of NP breaking the iron oxide molecules that compose them.
So the iron content of MIONs was determined using a ferrozine assay. In brief, 50
µl sample solution was mixed with equal volume of HCl 12 M and incubated at room
temperature for 30 minutes. Then, 240 µl of 2 M NaOH, 55 µl of 4 M ammonium
acetate and 110 µl of 5% hydroxylamine HCl were added to the solution. After
30 minutes incubation, the solution was mixed with 0.02% ferrozine solution. Light
absorption was read at 562 nm with 810 nm as the reference with a microplate reader.
This method is very useful to know the right concentration of produced nanoparti-
cles because it is impossible to estimate it taking into account the leaks during several
filtrations, washing and centrifuge processes.
During several batches of PEG-MNPs, the amount of recovered nanoparticles
ranges from 75 to 80% of total amount of iron used in the first steps of coating
process. [81]
5.1.7 Stability of MNPs
After a long coating process nanoparticles stay suspended in water. In this situation
they are pretty stable but after some days, weeks or months it is possible to notice
precipitates on the bottom of the storage vial.
In most cases these aggregates are formed by free DSPE-mPEG molecules that
interact with themselves and form precipitates.
MNPs have to be stable in different situations. To simulate them as good as
possible three categories are defined:
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• Storage: it is possible to store MNPs in water at different temperature and
different concentration
• pH: during several process it is possible that the pH of solution is not always 7
• particular solution: MNPs could be dissolved in many solutions with different
amounts of salts.
To verify stability, MNPs of a concentration of 100 ug/ml are suspended in different
solutions. After defined experimental time, the samples are centrifuged (2000 rpm for
10 minutes) and a little amount (about 10 ul) is taken from the top of solution. These
aliquots were analyzed with ferrozine protocol (5.1.6)to measure the concentration.
Storage:
To verify which is the best way to store MNPs, a big experiment was set up; nanopar-
ticles have been stored in water at different temperature (-80◦C, -20◦C +4◦C and
room temperature RT) with different concentrations (50, 100 and 500 ug/ml).
Figure 5.9 shows the percentage of MNPs remaining stable in solution. For in-
stance, if the value related to a sample is 80% this means that the 80% of amount
of iron is inside of suspendend MNPs while the 20% of iron is inside the precipitated
aggregates.
pH
The stability of MNP in different pH solutions has been tested in a experiment similar
with the previous one. Small MNP amount (50 µg) was suspended in 500 µl of pH
solution so the final concentration was 100 µg/ml. The vials that contained these
solutions have been maintained at room temperature for 3 and 6 days.
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Figure 5.9: Stability graph of MNPs sample at different storage conditions: concen-
tration and time
The pH value of used solution are: 1.92, 2.53, 3.30, 5.10, 6.00, 6.50, 7.40, 8.70,
10.90 and 12.00.
The data illustrated in figure 5.10 are normalized to 100% at starting value of
concentration.
From this graph it is possible to notice that the MNP are pretty much stable at
most pH value. The biggest problems has been found at boundaries pH value: 1.92
and 12 pH mainly.
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Figure 5.10: Stability graph of MNPs suspended in solution with different pH values
at 100 µg/ml concentration and maintained at room temperature for 3 and 6 days.
Particular solution:
The stability of MNP in different solution has been tested in a experiment similar
with the previous ones but using different buffer. These buffer are widely used in
many biological laboratory. Small MNP amount (50 µg) was suspended in 500 µl of
these buffer, so the final concentration was 100 µg/ml. The vials that contained these
solutions have been maintained on a shaker at 37 ◦ for 1, 3 and 5 days.
The buffer used for this stability experiment was:
• Fosfate buffer 10 mM ph7
• 2M KCl
• KCl 200 mM
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• CaCl2








• Water (as a control)
The data illustrated in figure 5.11 are normalized to 100% at starting value of
concentration.
From this graph it is possible to notice that the MNP are stable in most buffer.
There are problems with high concentration of ions buffer and with solution that
contain OH ions as KOH and NaOH, also at low concentration (0.4N KOH)
5.1.8 Chemical surface analysis of MNPs using ζ-potential
ζ-potential is the potential difference between the dispersion medium and the station-
ary layer of fluid attached to the dispersed particle.
In figure 5.12-left there is a scheme of ζ-potential of a general colloid.
This techniques measures the surface charge of structures. This is a important
parameter to know the stability of nanoparticles.
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Figure 5.11: Stability graph of MNPs suspended in different buffer at 100 µg/ml
concentration and maintained on a shaker at 37 ◦ for 1, 3 and 5 days.
The following table described the stability of colloid that have different values of
ζ potential.
ζ-potential [mV] Colloid stability
±[0, 5] Aggregation
±[10, 30] High instability
±[30, 40] Moderate stability
±[40, 60] Good stability
≥ 60 Excellent stability
Another reason to measure this potential is to understand the interaction with
lived tissue.
In previous section of this work the charge of MNPs was described as very funda-
mental parameter because a negative charged surface makes MNPs more biocompat-
ible, while a positive charge increases the interaction between MNPs and cells but is
more toxic too.
Figure 5.12-right shows ζ-potential analysis of PEG-MNP sample. It is to notice
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Figure 5.12: Left: scheme of surface potential of general colloid. Right: ζ-potential
measurement of PEG-MNPs
that the value is about -27.3 mV. And according with the table and the stability tests
of previously section it is possible to affirm the the MNPs are pretty stable
5.1.9 Magnetic T2 relaxivity of PEG-MNPs
All magnetic measures are executed using a 9.7T NMR Bruker Avance 400 spectro-
fotometer installed at the Bio-organic Chemistry of University of Trento.
The MNP sample are prepared by dilution from mother solutions 0.13 mg/mL
(=0.56 mM) in Fe3O4. Taking into account that a mole of Fe3O4 contains 3 mole of






+ r2 · C (5.1)
where T2 is the relaxation time T2 of
1H of water and C is the concentration of
iron expressed in mmol(Fe). The relaxivity unit is [sec−1 ·mmol(Fe)−1].
Table of relaxation time T2 is:
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And the following graph describe linear proportional relationship between concen-
tration n C and the inverse of relaxation time T2.
Fitting linear this graph, it is easy to find 1
T 02
= 5.456 ± 1.735 msec−1 and r2 =
109.9± 4.597 [sec−1 ·mmol(Fe)−1].
The relaxivity of other commercial product is: Feridex 160, Sinerem 160, Resovist
151 and Clariscan 35 [sec−1 ·mmol(Fe)−1]
Comparing them with our MNPs it is possible to affirm that the our value of
relaxivity r2 it is good enough for clinical practice.
5.1. SYNTHESIS AND COATING 99
5.1.10 X-ray photoelectron spectroscopy
All XPS analysis has been performed by Ph.D. Luca Minati at the FBK-IRST (Trento).
Iron oxide core
The survey allows the identification of the atomic species present in the sample. In
particular detect carbon (C1s peak at 285 eV) oxygen (O1s peak at 530 eV), iron (Fe
2p doublet at 710 and 720 eV) and traces of chlorine (component around 200 eV).
Other peaks derive from Fe3s and Fe3p components and from the Auger structures
of the detected elements.
Example of C1s peak fitting. The Core line shows a principal component a 285.0
eV associated to hydrocarbon chains, the component at 286eV is associated to -C-
O-C- and C-OH bonds while at 289eV falls the carboxylic bond. The C1s core line
is compatible with the presence of a high amount of oleic acid and oleamine chains
(used as surfactants) present on the nanoparticle surface. This is revealed also by the
extremely sharp peak at 285 eV (0.95 eV) that is an indications of the presence of
well ordered carbon chains as in the case of oleic acid and oleamine.
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The O1s core line presents one main component at 530 eV associated to metal
oxide. The additional three components at around 531, 532 e 533.5 eV are associated
to carbon- oxygen bonds.
The Fe2p core line shows two peaks coming from the spin-orbital splitting at
energies of 710 eV e 726 eV which are associated to iron oxide.
Application of spectral modeling to discriminate magnetite and hematite
in MNPs
Fe has different oxidation states giving origin to four different forms of iron oxides.
Wustite is formed by FeO in a cubic crystalline form. In magnetite Fe and O are
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arranged in an octahedral crystalline structure where iron assumes oxidation state 2
and 3. Hematite is formed by Fe2O3 and assumes a trigonal crystalline structure.
Finally maghemite can be considered as an oxidized form of magnetite where the pre-
vious forms coexists in a rather complex crystalline arrangement. In nature the more
diffuse form of iron oxide are magnetite and hematite. Also during the nanoparticle
(NP) synthesis of iron oxide nanoparticles leads to aggregates formed by different sto-
ichiometries between Fe and O composed prevalently by a mixture of Fe2O3 hematite
and Fe3O4 magnetite. Following the literature the maximal intensification of NMR
images is obtained using magnetite-based NPs. It is then important to estimate the
composition of the two different iron oxides inside the NP in order to possibly maxi-
mize the Fe3O4 content. Unfortunately the there are very small differences between
the Fe 2p spectral core lines of hematite and magnetite which render the discrimina-
tion between the two oxides and their quantification impossible. There is a second
problem which adds to this first difficulty. The inverse micelle process used to synthe-
sis the NPs leads to a considerable amount of polymeric residuals on the NP surface
as discussed previously. Unfortunately this kind of contamination contains a certain
amount of oxygen. It is not possible to use directly the O1s core line to quantify
the hematite and the magnetite considering the different Fe : O stoichiometries in
these two compounds. Although the problem is rather complex, a way to produce
meaningful estimation of the hematite and magnetite content in the NPs exists. It
is a method based on a statistical estimation. This work is referring to the Factor
Analysis (FA) which is quite used as an analytical approach in chemistry. Specifically
FA is able to determine the concentrations of some chemical components in a given
solution. The FA is a multivariate technique used to reduce matrices of experimental
data at their lower dimensionality. This is performed through specific transformations
of the original data (the XPS spectra) in new vectors in an abstract space. These
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transformations allow a reduction of the numbers of vectors needed to describe the
experimental observations. In our case the experimental data are XPS spectra and in
particular the valence band (VB) spectra. Using the FA it is possible to try to gener-
ate the XPS VB of the nanoparticles through a composition of the VB from hematite
and magnetite. The coefficients of this composition represent the concentrations of
hematite and magnetite in the MNPs.
A considerable part of the work was dedicated the development of a software to
perform data manipulation and the FA spectral analysis. The software was developed
in the Matlab since it is very efficient in handling matrices. As indicated in the
following flow chart, the program is roughly composed by two parts:
• Data manipulation to prepare data for the statistical analysis;
• Factor Analysis;
As stated above, the first step is to acquire the hematite and the magnetite stan-
dards to be able to generate the spectra from the NPs synthesized by the GT research
group. At this aim hematite 99.8% and magnetite 99.99% purity were bought from
Sigma Aldrich. High resolution XPS valence band spectra were acquired for each of
the two standards. Same experimental conditions were used to analyze the NPs from
GT. The valence bands of the standards are showed in figure 5.13
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Figure 5.13: XPS standard Valence band of Hematite (left), Magnetite (center) and
iron oxide core from GeorgiaTech (right)
The FA transforms these spectra in abstract vectors. It is important to verify that
these abstract vectors are able to reproduce the original experimental data. Results
are showed in figure 5.14-left and 5.14-center.
Figure 5.14: Comparison between real and model data of Hematite (left) and Mag-
netite (center). Right: Result of predictive model and real valence band
The abstract vectors are able to perfectly reproduce the original valence band
spectra of hematite and magnetite. If the hypothesis that the MNPs are composed by
hematite and magnetite holds for true, components 1 and 2 should be able to correctly
reproduce the valence band spectrum of the GT- MNPs. The result obtained from
the Factor analysis is shown in 5.14-right
As it can be appreciated a good reproduction of the MNP valence band which is
obtained using 38% hematite and the 62% magnetite. [82]
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PEG coated MNPs
After XPS core analysis, measurements of PEG-MNPs has been done.
In fig. 5.15-left the C1s core lines of the SPIO NPs before and after the reaction
with the PEG chains are reported. The as-produced SPIO NPs show an intense
carbon signal placed at 285 eV associated to the presence of hydrocarburic chains.
These are ascribed to the presence of the oleic acid and oleamine stabilizing agents
on the surface of the NPs. The presence of hydrocarburic chains clearly explains the
hydrophobicity of the SPIO NPs. After the reaction with the polyethylene glycol, the
C1s core line show the presence of a high intensity peak at around 286 eV assigned
to the CH 2 -O- bonds that are the fingertips of the PEG chains.
Figure 5.15: X ray photoelectron spectroscopy analysis of the C1s core line of pristine
SPIO NPs (dashed)
Finally, the C1s core line of the SPIO-PEG nanoparticles shows the presence of a
small feature at around 289 eV associated to the carboxylic groups of the oleic acid
chains [12]. The same feature visible on the C1s core line of the pristine SPIO NPs
proves the bond formation between the hydrophobic portion of the phospholipid-PEG
polymer and the oleic acid chains. As a result of this hydrophobic interaction, the
SPIO-PEG nanoparticles show high solubility in water. [83]
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5.2 Functionalization
Iron oxide nanoparticles have two main properties with consequent advantages: nano-
metric size and paramagnetic behavior.
So these MNPs could be exploited just as MRI contrast agents.
To make these MNPs usable as carrier for drug delivery, it is necessary to func-
tionalize them to entrap drug, to label with fluorescent dye and to improve uptake
by cells.
5.2.1 Labeling with fluorescent dye
Obtain fluorescent skill for our MNPs it is very useful since it allows us to give
another property to nanoparticles other than magnetic behavior. It is used a specific
dye, which is called DiI. In following figure there are the structure and the absorption-
emission spectrum of this molecules. The values of absorption and emission are so
strong that this molecule can be used as colorimetric and fluorescent probe.
This molecule is hydrophobic and can be entrapped inside the hydrophobic shell
of MNPs, formed by oleic acid and phospholipid chains. When the dyes enter this
shell, the entire MNP becomes a fluorescent probe.
The protocol to obtain an effective entrapment included:
• PEG-MNPs suspension in water
• DiI molecules suspension in DMSO
• MIx of PEG-MNPs and DiI solutions at [MNP ][DiI] = 80µg/ml5µg/ml = 16
Figure 5.16-bottom shows the difference between spectra and max intensity for a
fixed wavelength value of MNPs with and without dye. This graph confirms that DiI
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Figure 5.16: Top: Structure (left) and absorption and emission spectrum (right) of
DiI dye. Bottom: Absorption spectrum (left) and absorbance at 550 nm (right) of
MNPs with and without DiI
molecules can be used for example, as fluorescent probes for confocal microscopy and
cytofluorimetry
In figure 5.17 two different confocal microscope images are showed This pictures
are taken with different methods: different cells, different instruments and different
staining preparation; but in both cases it is clear that MNPs are locate inside the
cells but not inside the nucleus.
One possible improvement to complete the project purpose is to label MNP with
different dyes, so it would be possible to exploit these properties to verify different
behaviors. For example, if two types of MNPs with different properties (different
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Figure 5.17: 2 examples of confocal microscope images taken using DiI-MNPs. Left:
ES2 cell staining to map cell nucleus (DAPI, blue), cytoskeleton (Oregon Green Phal-
loidin, green) and MNPs (red). Right: 3T3 cell staining to map cell nucleus (DAPI,
blue) and MNPs (red)
antibodies, drugs, charge, size,...) ore labeled with two different color it would be
easy to understand the behavior of the 2 MNPs in the same experiment reducing the
costs and saving time.
5.2.2 Antibody conjugation to MNP
A good idea to improve the uptake of MNPs by cells is to increase their reciprocal
interaction. To do this it is possible to use a lot of specific molecules designed to
promote diffusion of MNPs into cells. But this molecules could probably interact
with all types of cells (healthy or diseased) and this is not good because for drug
delivery it is important to enter only the tumor cell. For this reason, the ligand
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selected to specifically enter tumor cells is the antibody for epidermal growth factor
receptor EGFr.
The epidermal growth factor receptor (EGFr; ErbB-1; HER1 in humans) is a
receptor located on cell membrane. It is a member of the epidermal growth factor
family (EGF-family) and belongs to extracellular protein ligands. Epidermal Growth
Factor was discovered by Rita Levi-Montalcini for which received the Nobel prize in
Physiology or Medicine in 1986.
Mutations affecting EGFr expression or activity could result in cancer. This is
very important for the purpose of the project because the majority of cancer cells has
high gene expression of this specific protein.
This protein is important for cancer cell because regulates the viability and pro-
liferation of cells. A high concentration of this on the membrane surface can increase
the cellular proliferation rate.
The EGFr antibody has been produced by specific hybridoma cells by dr. Valeria
Antonini (CNR-IBF, Trento). The entire process is described in section 6.3.
The first method used to attach EGFr to MNP is based on thiol-maleimide reac-
tion. The iron oxide cores were coated with a mixture of DSPE-mPEG and DSPE-
PEG-maleimide. The weight ratio between total DSPE-PEG and iron was 8:1 and
the molar ratio of DSPE-PEG-maleimide in the mixture was 2% (following structure).
The disulfide bond in the antibody was reduced with 2- Mercaptoethylamine-HCl.
After 2-Mercaptoethylamine-HCl was removed by a centrifugal filter tube (MW =
10,000, Millipore), the reduced antibody was mixed with the MNPs in PBS solution
at 1:1 ratio and incubated at 4◦C overnight. Free antibody fragments were removed
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by ultracentrifugation.
In the preliminary test this method worked very good, but the presence of maleimide
compromised the stability of nanoparticles because this functional group is very re-
active.
To fix this problem another way to bind the antibody has been developed. The
nanoparticles were coated with mixtures at DSPE-mPEG-2000 and DSPE-PEG-NH2-
2000 (1,2 and 5%) different ratio. At this point a crossilnker to bind the AB to MNP
was used: this crosslinker is Sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (Sulfo-SMCC) provided by Thermo Fisher Scientific Inc.
This molecule is used as bridge molecule between amine groups of MNP and
sulfhydryl groups of antibody, treated with 2-Mercaptoethylamine-HCl in the same
way described before. A scheme protocol is described in figure 5.18. In this way, there
is a step more respect to the previous method, but the MNPs coated with DSPE-
PEG-NH2 are more stable (months at 4◦C) respect to the same MNPs coated with
DSPE-PEG-malemide (2-3 days at 4◦C).
The nanoparticles functionalized with EGFr antibody are called AB-MNP.
Determination of MNP targeting using mouse IgG on ELISA plate
To verify the presence of antibodies o MNP surface, a ELISA-ferrozine hybrid protocol
has been developed.
First, a 96-well ELISA plate was coated with mouse IgG specific for EGFr antibody
suspended in bovine serum albumin (BSA). In brief, mouse IgG was dissolved at 2
µg/ml in PBS. Serial dilutions of the IgG solution were performed directly in the
plate. The plate was incubated at 4◦C for 24 hours and washed with PBS containing
0.05% Tween-20. Then, the plates were incubated with 1% BSA solution in PBS at
4◦C for 24 hours. In the coated plate, the amounts of mouse IgG were different but
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Figure 5.18: Scheme of antibody binding using DSPE-PEG-NH2 and Sulfo-SMCC
crosslinker
the BSA was approximately the same on the surface of each well.
Each well was loaded with 100 µl of AB-MNPs. The concentrations of the MIONs
were fixed at 2 ug/ml. The plate was incubated at 37◦C for one hour and washed with
PBS containing 0.05% Tween-20. To measure the amount of bound MIONs, the wells
were incubated with 50 µl of 6N HCl for 30 minutes at room temperature. Then 120
µl of 2 N NaOH, 25 µl of ammonium acetate buffer, 25 µl of 5% hydroxylamine HCl
and 30 µl of 2% ferrozine were added sequentially. The iron content was determined
by light absorption at 562 nm with 810 nm as reference.
The following table illustrated the amount combination between MNP, crosslinker
and antibody.
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MNP 1%, 2% and 5% EGFr antibody Crosslinker Sulfo-SMCC
400 µg 100 (low) and 200 (high) µg 60 µg
2:1 and 1:1 MNP/AB molar ratio 1500:1 MNP/SMCC molar ratio
Figure 5.19 shows the results about effectiveness of binding using MNPs with
different amount of amine group and different concentration of antibody.
Figure 5.19: ELISA analysis of MNPs with and without antibody.
The type of nanoparticles that returned better results was 5%-AB-MNPs showing
higher values for both low and high AB concentration. From this point this protocol
with these parameter has been used for following tests and results. For simplicity the
5%-AB-MNPs are called AB-MNP.
These AB-MNPs were tested to verify if the presence of AB facilitates MNP uptake
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by cells and these results will be showed in vitro test part (section 6.4.3)
5.3 Drug loading
One of the most important thing during the design of a carrier for drug delivery is the
loading and release of drug. For this purpose doxorubicin (DOX) has been selected
as a standard drug. Doxorubicin is a very used drug for cancer therapy. Furthermore
DOX has been chosen for its chemical properties:
• Hydro -phobic or -philic behavior is pH sensitive.
• it possible to use it as fluorescent probe: it has excitation and emission at 480
and 580 nm.
Taking into account the behavior at different pH, the drug could be entrapped
inside the hydrophobic layer of MNPs in the same way of DiI fluorescent dye.
To get acquainted with the behavior of this molecules and with the protocol, the
first DOX entrapping procedure was carried on using water solution (pH 6.5) starting
from the parameters used with DiI dye.
One of main problem of drug entrapment is the elimination of free drug from solu-
tion of nanoparticles. The method use in these preliminary tests is ultracentrifugation
exploiting the big difference between drug (500 Da) and MNPs (380 kDa) molecular
weight.
This work is still in progress; the first thing has been done is the evaluation of
the correct ratio between drug and MNP to obtain the better loading. Different
DOX:MNP ratios have been analyzed to verify which one is the best producing a
higher drug loading: 2, 5, 10 and 50 ug of DOX for 80 ug of MNPs (1 ml solution
with a concentration of 80 ug/ml).
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Just for a complete information, there is a experimental protocol, developed in
collaboration with Georgiatech, to measure χ value. χ is an indicator of entrap
efficiency of drug carrier. It is calculated after a centrifugation of solution with MNPs
and free drug as described in figure 5.20.
Figure 5.20: Process to prepare the solution for χ analysis
The physical principle of this technique is:
CD−Total = CD−free + CD−entrapped = CD−free + χ · CSPIO (5.2)
where CD−Total is the total amount of drug, CD−free is free drug, CD−entrapped
is drug entrapped in MNPs and CSPIO is MNPs concentration of solution.
Taking into account that CTD−freeOP = C
BOTTOM







and it was observed that χCfree is constant for different samples.
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To try this method samples (2, 5, 10, 50 ug of dox for 80 ug of MNPs) have been
used.
The following table reports the results for each sample:
ug 2 5 10 50
χ(10−3) 6,26 6,96 7,40 2,80
χ
Cfree
0,0017 0,014 0,011 0,001
From this data it is possible to affirm that the 10 ug has a better entrapping
because its value is the highest respect to others. Also the value of χ/Cfree is pretty
similar for all samples but the 50 ug, that has a concentration too high for this amount
of MNPs as showed before.
All this preliminary data have been produced handling DOX in water solution.
For a complete analysis it is important to verify drug behavior as regards stability,
light absorbance and fluorescence at different pH.
The used pH values are: 1.92, 2.63, 3.3, 5.1, 6, 6.5 (dH2O), 7.4, 8.7, 10.9 and 12.
Figure 5.21: Picture of DOX molecules suspended in different pH solutions: solutions
between 1.92 and 7.40 are stable, the 8.70 pH solution have drug aggregates inside
and upper pH values show particular stability and absorbance properties.
The stability of DOX solution is illustrated in figure 5.21: it is possible to notice
that at pH 8.7 DOX molecules become hydrophobic and aggregate. Both at lower
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and higher pH, DOX seems stable. At pH 10.9 and 12 the chemical structure of DOX
molecules is probably modified because the solutions change color and no precipitation
was observe.
In figure 5.22-left it is possible to analyze what happens at the fluorescence signal
and light absorbance of DOX molecules at different pH.
Both parameters are stable for low pH from 1.92 to 7.4 and start to be not so
effective at higher value of pH. This is a good thing because high value of pH is
just used to entrap DOX into MNPs, but the release happens at low pH (inside the
lysosome: 3-4 pH) and the drug has to be active and useful in this condition.
Figure 5.22: Left: Graph of fluorescence and absorbance signal of nanoparticles with
and without doxorubicin DOX. Right: Graph of fluorescent signal and absorbance at
480 nm of DOX at different pH values
It is interesting to notice that MNPs with and without entrapped DOX molecules
show different fluorescence and absorbance behavior (figure 5.22-right). Both fluores-
cence and absorbance spectroscopies will thus allow to measure the amount of DOX
entrapped in the MNPs preparing a standard curve with fixed amount of MNPs (7
µg) and different concentration of DOX ranging from 0 to 100 µg. The measured
value is 1.1 µg/ml of DOX for 35 µg/ml of MNPs.
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Taking into account our experience with doxorubicin and nanoparticles, it is easy
to affirm that one of the most complicated step is the removal of free DOX molecules
form DOX-MNPs solution.
several methods have been tested and many others are still underdeveloped to
obtain a solution as free as possible from DOX molecules.
The method used and to try is: ultracentrifugation, magnetic separation, filtration
by filter tube, desalting by spin column, dialysis and many others.
Each of this methods has some disadvantages: they are time consuming, very
expensive, MNP leaking and other problems.
At the same time, new DOX entrapment protocol based on different pH solution
will be tested. Once obtained best drug loading, MNP will be tested to measure
release.
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5.4 Material, Reagent and Instruments
5.4.1 Experiment materials of chapter 4
The used reagents are described in the following table:
Nome Company Code Purity
Iron(III) chloride hexahydrate Sigma-Aldrich 31232 > 99.0%
Iron(II) chloride tetrahydrate Sigma-Aldrich 220299 > 99.0%
Aerosol AOT Fisher B01930 100.0%
Sodium Hydroxide Sigma-Aldrich 480878 99.98%
n-Hexane Sigma-Aldrich 139386 > 99.0%
Acetone Sigma-Aldrich 179124 > 99.5%
Methanol Fluka 65550 > 99.5%
Toluene Sigma-Aldrich 24529 > 99.5%
The used instruments were:
• The used transmission electron microscope is a TEM Philips CM12 spectrom-
eter equipped with EDAX 9100. The Olympus is a CCD MegaView II. The
acceleration voltage is between 20 and 120 KV, the resolution is 0.3 nm and the
magnification is of between 46x to 280.000 x.
• The size distributions were analyzed by Malvern’s Zetasizer 1000. The laser
mounted on the instrument had a wavelength of 690 nm. The diffusion of light
was measured at an angle of 90 degrees.
• The XPS measurements on MNP were carried out using an ESCA200 instrument
(Scienta-Gammadata ESCA 200 Uppsala Sweden)
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5.4.2 Experiment materials of chapter 5
Section 5.1
MNP core were provided by Laboratory of Biomolecular engineering and Nanomedicine
at GeorgiaTech in Atlanta (US)




DSPE-PEG- amine 2000 880128P
Toluene (24529) and Chloroform (650498) was supplied by Sigma-Aldrich. While
the filtration tube was a commercial product for Sartorius: Vivaspin 20 (VS2002)
with a cutoff of 10 kDa.
The used instruments were:
• The ultracentrifugation was a BeckMan Coulter Optima L-100K. The used rotor
was: 70.1 Ti Rotor, Fixed Angle, 12 x 13.5 mL, 70,000 rpm, 450,000 x g
• The used trasmission electron microscope is a TEM Philips CM12 spectrom-
eter equipped with EDAX 9100. The Olympus is a CCD MegaView II. The
acceleration voltage is between 20 and 120 KV, the resolution is 0.3 nm and the
magnification is of between 46x to 280.000 x.
• The size distributions were analyzed by Malvern’s Zetasizer 1000. The laser
mounted on the instrument had a wavelength of 690 nm. The diffusion of light
was measured at an angle of 90 degrees.
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• The XPS measurements on MNP were carried out using an ESCA200 instrument
(Scienta-Gammadata ESCA 200 Uppsala Sweden)
• The used atomic force microscope is a AFM NT-MDT Solver Pro software and
NOVA. The height and phase are acquired in the mode of intermittent contact
with non-contact tips with curvature typical of 10nm and spring constant of 5.5
N / m, the typical frequency resonance: 150 kHz.
• The used transmission electron microscope is a TEM Philips CM12 spectrom-
eter equipped with EDAX 9100. The Olympus is a CCD MegaView II. The
acceleration voltage is between 20 and 120 KV, the resolution is 0.3 nm and the
magnification is of between 46x to 280.000 x.
Section 5.1.4
In this part materials and instruments are similar to the previous one, the only dif-






All reagents are provided by Sigma Aldrich and are listed in the following table:







To measure the absorbance of samples produced by ferrozine prococol, a mi-
croplate reader TECAN Infinite 200 PRO series has been used.
Section 5.1.8
To measure the ζ-potential of MNP solution a Malvern Zetasizer Nano Z has been
used.
Section 5.2.1
For the labeling of MNP a fluorescent dye has been used. This dye was provided by
Invitrogen, Life Technologie Corp.
The chemical name of this product is 1,1’-Dilinoleyl-3,3,3’,3’-Tetramethylindocarbocyanine,
4-Chlorobenzenesulfonate, called DiI. The product code is D-7756
To produce fluorescent images a confocal microscope has been used: Nikon A1.
The excitation wavelength of this instrument are: 457, 488 and 514 nm.
Section 5.2.2
In this part a lot of new reagents have been used.
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Nome Company Code
DSPE-PEG(2000) Maleimide Avanti Pola Lipids Inc. 880126P
2-MercaptoethylamineHCl Thermo Scientific 20408
Sulfo-SMCC Thermo Scientific 22322
Unconjugated Horse Anti-Mouse IgG Antibody Vector Lab. AI-2000
Section 5.3
The used drug in this part was supplied by Sigma Aldrich. The commercial name is
Doxorubicin hydrochloride and its product number is D1515.
To measure the absorbance and the fluorescent of samples loaded with DOC, a
microplate reader TECAN Infinite 200 PRO series has been used.









The general aim of this part is to investigate interactions and effects of nanoparticles
on tumor cell lines. In particular the cytotoxicity has been investigated: internaliza-
tion and localization of the nanoparticles in different condition. All the experiments
are performed in vitro using both 2D and 3D cell cultures.
Preliminary studies has be done on the delivery and availability of the NP and/or
drug into the cytosol or intracellular targets.
The cell lines used in this part of work belong to 3 different types of cancers. They
are:
• Lung cancer: >30% estimated death; it is considered one of the most difficult
solid tumours to be targeted. Lung cancer incidence in females is raising, due
to the fact that while the number of men who smoke is decreasing, the number
of females who start smoking is still increasing. App. 20% of all lung cancers
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are independent of smoking.
• Colon cancer: >10% estimated death; invasive and if recognized too late,
metastasis to the liver, bone, etc.
• Ovarian cancer: ˜4% of estimated new cases in females =¿ attention to gender
issues.
Five cell lines has been chosen to start our analysis. They are list in the table
below.
Type Cell lines EGFR expression level
Colon Cancer HCT116 Intermediate
HT29 High
Ovary Cancer ES2 High
Lung Cancer A549 Intermediate
KNS62 Not determined
The use of all these cell lines would determined a huge work, hence only some of
these were used, in particular HT29, ES2 and HTC116.
Other cell lines has been used for test: 3T3 fibroblast and SW480 colon tumor
cells. These cells show a negative gene expression for EGFr.
6.2 Cell characterization
Flow cytometric
By flow cytometry the EGFr protein expression has been tested of five cell lines
(HTC116, HT29, ES2, A549, KNS62) plus 2 negative ones (SW480 and 3T3 cell
lines).
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Analysis has been performed two weeks after the cell thawing. In order to confirm
the EGFr expression was no lost by cells during the culturing time the analysis was
repeated also 1 month and 50 days after. Selection pressure for high EGFr expression
was kept adding recombinant EGF (5 ng/ml for 3 days) on the 21st and 47th days,
just few days before the 2nd and 3rd cytofluorimeter analyses. Analysis was repeated
3 times:
• 1st experiment: 16 days after cell thawing
• 2nd experiment: 15 days, and 50 days after cell thawing
• 3rd experiment: 14 days, 28 days, and 50 days after cell thawing.
In all the analyses each cell line was tested for: cell without antibody (CTRL), a-
human EGFr-1 Abs + FITC (fluorescein) secondary Abs (aEGFr), FITC (fluorescein)
secondary Abs (FITC) and PSMA (Prostate Specific Membrane Antigen) Abs + FITC
secondary Abs (D2B)
The data obtained show that EGFr expression early time points (14th-15th-16th
days after thawing) are similar in the 3 different analyses. In the 3rd analysis SW1990
lost EGFr expression after 28 days. At 50th day the most of the cell lines still express
EGFr. Another important result is that SW480 and 3T3 are EGFr negative, as it was
expected from the Affymetrix data.
These data were obtained with the collaboration of dr. Valeria Antonini (CNR-
IBF, Trento)
6.3 Production of EGFr antibodies
A big amount of antibody was needed in order to make targeting nanoparticles. This
is why it was decided to produce them by ourselves. The entire process and showed
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Figure 6.1: Flow Cytometric analysis at different culturing cell times using anti human
EGFr1, FITC, and PSMA. This data is obtained with the collaboration of dr. Valeria
Antonini (CNR-IBF, Trento)
results were carried out by dr. Valeria Antonini (CNR-IBF, Trento). HB-8508 hy-
bridoma was purchased from ATCC. It’s B lymphocyte type hybridoma produced in
animals that were immunized with partially purified EGF receptors from A-431 cells.
Spleen cells were fused with NS-1-503 myeloma cells. The produced antibody is a
mouse IgG1 Abs clone 225 that blocks EGF/TGF -induced activation of EGFr and
efficiently arrests tumor growth in vivo. It has no effect on tyrosine kinase activity of
the receptor. The antibody binds to a single class of receptor sites on A-431, HeLa
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and human fibroblasts, and it blocks EGF stimulated phosphorylation of membrane
proteins.
6.3.1 Hybridoma Adaptation to Medium without Horse Serum
In order to make all the purification protocol easier it was tried to culture the hy-
bridoma in medium without the presence of serum. Different kinds of medium has
beeen used and Hybridomed Medium (Biochrom AG) turned out to be the one giving
the best performance.
Figure 6.2-left shows western blotting analysis of hybridoma IgG production after
4 day culturing. The arrows indicate the IgGs present in the supernatant of the
hybridoma cultured with Hybridomed Medium without serum. Also reduced and not
reduced conditions are shown.
6.3.2 IgG production
For production of IgG antibody, CELLine Two-Compartment bioreactor technology
(IBS integra Biosciences) was used. This system is designed to overcome the problems
of oxygen and nutrient supplying and inhibiting metabolic waste products removal.
At the same time it enables cell proliferation to very high cell density within the
cell compartment. In order to establish a working protocol, supernatants at different
time points were harvested, and both cell density viability and expression of Abs were
checked. Nine days culturing resulted to be the best supernatant harvesting time.
Figure 6.2-right shows western blotting of IgG production at different times. Also
reduced and not reduced conditions are shown.
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Figure 6.2: Left: Western blotting of hybridoma IgG production after 4 day culturing.
The arrows indicate the IgGs present in the supernatant of the hybridoma cultured
with Hybridomed Medium without serum (reduced and not reduced conditions are
shown). Right: IgG production time points: western blotting of different harvesting
time points. Reduced and not reduced conditions are shown. Legend: (1) 2 days
reduced, (2) 4 days reduced, (3) 7 days reduced, (4) 9 days reduced, (5) medium,
(6) 2 days not reduced, (7) 4 days not reduced,(8) 7 days not reduced,(9) 9 days not
reduced,
6.3.3 IgG purification
Supernatant was first filtered (0.22 µm) and then loaded onto a protein G sepharose
column. IgGs were eluted using 0.1 mM glycine pH 3 (1M tris-HCl to neutralize the
eluate). The sample was collected and it was dialyzed against PBS in order to remove
all the amino groups of the buffer that could create problems during the IgG linking
to the nanoparticles.
Comassie staining gel of IgG purification steps (reducing and not reducing condi-
tions) are showed in following figure.
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Figure 6.3: Comassie staining gel of IgG purification steps. Reducing and not reducing
conditions are shown.
6.3.4 EGFr IgG quality testing
The quality of the produced antibodies was tested both by flow cytometry and cell
proliferation inhibition analyses. FACS analysis of AsPc1 pancreas cell line using the
EGFr antibody purchased by AbCam (left panel) and the EGFr produced by us (right
panel) are compared in the figure below. As shown, the antibody worked fine in flow
cytometric test.
Moreover antibody effects on 8 cell lines (ES2, HCT116, HT29, KNS62, A549)
thawed 1 week before the experiment was tested by viability analysis. 10.000 cells of
each cell lines were plated in 96 wells Costar. After 6 hours they were treated with
EGFr 200nM. After 18 hours and 42 hours the number of viable cells was determined,
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Figure 6.4: Cytometric analysis of AsPc1 cell line using the EGFr antibody purchased
(AbCam ab30) left panel and the EGFr produced by us (right panel)
as reported in the next two tables.
Viability relative to untreated cells after 18hrs:
HT29 HTC116 ES2 A549 KNS62
CTRL 100 100 100 100 100
aEGFr 200 nM 38 92 96 93 77
Viability relative to untreated cells after 42hrs:
HT29 HTC116 ES2 A549 KNS62
CTRL 100 100 100 100 100
aEGFr 200 nM 8 66 72 73 94
After 42 hrs of treatment almost all the cell lines show a decreased cell numbers
except SW1990 and SW620 both the 1week and 2months old cells cultures. This
indicates that the antibody can arrest cell proliferation or can induce cell death.
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6.4 GATECH MNPs
All experiments of this section are carried out using 5%-NH2-PEG-MNP (or PEG-
MNP simply). These MNPs, dependent on type of experiment are functionalized with
fluorescent dye (DiI-MNP), EGFr antibody (AB-MNP and DiI-AB-MNP) and DOX
drug (DOX-MNP).
6.4.1 Interaction NP-cell
A first step is to investigate the direct interaction of the NPs (in the absence of
any drug) with the selected cell lines, using particles with different sizes and coat-
ing/functionalization. Preliminary analysis on the viability of ES2 cell lines after 2
and 4 day incubation with PEG-MNP at 35 ug/ml concentration has been performed.
The results (fig. 6.5-left) shows that cell treated with MNPs feel the presence of
these structure and the proliferation is slowed down. But it is possible to affirm that
the MNPs are biocompatible.
Figure 6.5: Left: Alamar test to very viability of ES2 cell treated with PEG-MNP.
Right:Comparison between viability of ES2 cells treated with MNPs and iron ions
134 CHAPTER 6. IN VITRO TESTS
6.4.2 Toxicity of MNPs
In previous section, experiment described that MNPs are biocompatible. But to inves-
tigate in depth the interaction between MNPs and cells, it is interesting to evaluated if
the possible iron ions released by nanoparticles can modify viability and proliferation
of cells.
The parameters of this experiment are:
• ES2 cell lines
• cell medium with MNPs (iron concentration of 35 µg/ml)
• cell medium with iron ions (iron concentration of 35 µg/ml)
• alamar blue test to measure cell viability after 24 and 48 hours
In figure 6.5-right it is possible to notice a behavior similar to previous case.
Cell without treatment proliferated faster than cell with iron or MNPs in medium.
Other cells have pretty much the same behavior: presence of iron and MNPs modifies
proliferation and viability, but this change can not be correlated just to concentration
of ions or to structure of MNPs.
6.4.3 Measurement of uptake of AB-MNP by cells
One of most important analysis to reach objective of the project is the measurement
of uptake of MNPs by the cell. This parameter gives useful information to design
a perfect carrier for diagnosis and above all drug delivery. Knowing the amount of
MNPs enter the cell, it is possible to understand the right dose of MNPs to inject.
As described in section 5.2.2, the antibody is attached on the MNP surface ex-
ploiting malemide groups of Sulfo-SMCC crosslinker. One of interesting things to do
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it very if presence of antibody or malemide increases uptake by cells respect to not
functionalizated PEG-MNP.
To check this possibility, a experiment with 5 different kinds of MNPs has been
set up.
• MNP: nanoparticles just with PEG-MNP;
• Cross: nanoparticles with Sulfo-SMCC crosslinker;
• Cross+Block: nanoparticles with Sulfo-SMCC crosslinker and cysteine;
• AB-MNP: nanoparticles with attached AB and free crosslinker;
• AB-MNP+Block: nanoparticles with attached AB and free crosslinker and cys-
teine;
Cysteine transform the maleimeide group in a COOH group that does not modify
the MNP uptake by cells.
To be more precise as possible, also two cell lines has been used:
• ES2 ovary cell: EGFr high gene expression
• SW480 colon cell: negative control
with 4 days of MNP incubation.
To analyze the amount of iron inside the cell has been used the ferrozine protocol
(fig 6.7-left): this is a quantitative technique to measured the concentration of MNPs
inside the cell using colorimetric method described in section 5.1.6
The figure 6.4.3 shows the MNP uptake measured with ferrozine method. For the
ES2, it is possible to notice that the AB-MNP enter easier the cell respect to other
samples. The different of obtained values with or without blocking is not essential.
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Figure 6.6: Left: Measurement of MNP uptake in ES2 cell line - Right: Measurement
of MNP uptake in SW480 cell line
For SW480 cell line, there are not different between MNPs with or with antibody
or blocking.
According to this data, it is possible to affirm that the presence of maleimide
group does not increase or decrease the MNP uptake by cell.
Taking to account this results and to prepare the future in vivo test, another cell
line has been selected; it is a EGFr high gene expression cell line: it is HT29 colon
cancer cell.
In addition to ferrozine protocol, cytofluorimetry technique has been used to mea-
sure MNP uptake by cell (described in fig. 6.7-right). In this technique MNPs become
fluorescent when functionalized with DiI dye. This is an advantage because the MNPs
that enter cells that become a fluorescent structure. So it is possible to verify the
relative amount of uptaken DiI-MNP using a FACS cytofluorimeter.
With both techniques, the uptake has been analyzed using cells with a high gene
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expression for EGFR (HT29) and with negative control (3T3) to verify if the presence
of the antibody is important for the internalization of MNPs.
The experimental times for FACS are 1 and 3 hours and for Ferrozine is 4 days.
Figure 6.7: Ferrozine and FACS methods to measure the uptake of MNPs by cells
Figure 6.8 shows the iron ion amount for both cell lines and for MNPs with and
without AB. It is possible to affirm that AB-MNP enter easier the cells with a high
gene expression respect to MNP without antibody. While the behavior of MNPs with
and without AB is very similar.
6.4.4 Effectiveness of DOX entrapped in MNPs
At this point it is interesting to verify if chosen drug is effective to kill cell and to test
if DOX-MNP if effective as free DOX.
The first thing to do is to verify if the DOX concentration inside the MNPs are
good to kill cell. In section 5.3 the concentration of DOX inside MNPs has been
calculated and this value is 1.1 µg/ml of DOX for 35 µg/ml of MNPs.
Taking into account this value, experiment has been set up with the following
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Figure 6.8: Uptake results for HT29 and 3T3 cells using MNPs with and without
antibody
parameters:
• ES2 and HT29 cell lines
• 3 different DOX concentration in medium: 11 µg/ml (DOX10), 1,1 µg/ml
(DOX1) and 0,11 µg/ml (DOX01).
• alamar blue test to measure cell viability at t0 (starting point before MNP
diffusion), 1, 2, 3, 5 and 8 days for ES2 and t0, 2, 3, 5 and 7 days for HT29
Results for both cell lines (fig 6.9 shows that higher concentration of DOX (11 and
1 µg/ml) have a good efficacy in the first 3 days. For low concentrations cell viability
has strange behavior.
For ES2, DOX starts to kill cells after 5 days, probably this drug needs an ac-
cumulation to be effective. For HT29, in the first days low concentrations have the
same behavior of DOX10 and DOX1, but afterwardt cell proliferation start to in-
crease again. One possible reason is that in first days t cell proliferation and cell
dying are balanced; in the following days there is a imbalance in favor to proliferation
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Figure 6.9: Alamar blue test to verify viability of cell trated with different concentra-
tion of DOX drug: 11 µg/ml (DOX10), 1,1 µg/ml (DOX1) and 0,11 µg/ml (DOX01).
Left: ES2 cell line. Right: HT29 cell line
and number of cell increases.
Taking into account these results, it is easy to prepare an experiment to verify
the efficacy of MNP loaded with DOX drug. Parameters are similar to previous
experiment, but in this case there are 3 different samples:
• free DOX with a concentration of 1,1 µg/ml (DOX1);
• MNP loaded with drug following the protocol described in the first part of
section 5.3, iron concentration of 35 µg/ml (DOX-MNP);
• common PEG-MNP: they are the same used to prepare DOX-MNP (MNP).
Other parameters are:
• ES2 and HT29 cell lines
• alamar blue test to measure cell viability at t0 (starting point before MNP
diffusion), 2 and 4 days
Fgure 6.10 shows the behavior of viability of cells treated with different samples.
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For both cell lines, control cell (CTRL) and cell with DOX (DOX1) follow the
same trend of previous experiment. CTRL cells continues to proliferate day by day.
Conversely, the DOX1 cell population tends to zero after 4 days.
Figure 6.10: Alamar blue test to verify viability of cell treated with different sam-
ple: free DOX drug (DOX1), nanoparticles loaded with DOX (DOX-MNP) and just
nanoparticles without drug (MNP). Left: ES2 cell line. Right: HT29 cell line
For DOX-MNP sample two different things happen dependent on types of cell
line. For ES2, the only one effect of DOX-MNP is to limit the proliferation of cell
that become retarded. On the contrary, DOX-MNP effect on HT29 is better: after
growing for 2 days, the number of cell starts to decrease. But after 4 day, their effect
is not so efficacious as free DOX.
For MNP sample something strange happens for both cell lines. This sample of
nanoparticle without drug kills cells in a similar way to free DOX, in particular in case
of ES2 cell line. There are possible reasons to explain the particular behavior of MNP
sample respect to DOX-MNP tes and they are illustrated in following paragraphs.
As described in section 5.1, after coating, PEG-MNPs are purified with filtration
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tube, vacuum pump and ultracentifugation. After this batch, MNPs are stored in 4C
fridge, ready to use.
The protocol to produce DOX-MNP starts taking an aliquot of this MNPs and
continues as described in section 5.3. Cell medium solutions with MNPs and DOX-
MNP are prepared adding small quantity of MNPs (with few number of washing
steps) and DOX-MNP (more purified). Probably this difference of purification can
show strange behaviors of previous tests. It is possible that MNPs contain traces of
chloroform or toluene from coating process. Also small amounts of this molecules
(parts per million ppm) can be very toxic for all types of cells.
Correlated with this explanation, there is another possible reason: the difference
in purification steps can modify the ζ-potential of MNPs. Different superficial charge
could modify the interaction of MNPs with the cells and MNPs may result toxic or
not totally biocompatible.
Figure 6.11 shows the ζ-potential curves of MNPs and DOX-MNP samples.
Figure 6.11: Zeta potential curve of MNPs and DOX-MNP samples
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It is possible to notice that MNP sample has a peak more shifted to right respect
to DOX-MNP. This modification of superficial charge can change the interaction of
nanoparticles with cells. morover MNP sample has a bigger positive component, that
can increase the interaction with the cells but it is toxic too.
In the next experiment, nanoparticles to use as MNPs and DOX-MNP sample
have to stand the same better purification and washing protocol to eliminate traces
of solvent and to have similar ζ-potential
6.4.5 Bioreactor experiment: Introduction part
Until now all in vitro tests have been done in regular culture method. Cells have been
seeded on the bottom of wells of commercial plate. The cell medium, with or without
nanoparticles, was added on top of them. All measures has been carried out with a
regular 2D layer of cell attached on well bottom.
Referring to future in vivo tests there are two things to take into account:
• cancer cells that form a neoplasm are not in a bidimensional layer but in a more
complex 3D structure.
• MNPs are injected in blood stream, so when they interact with cell are moved
by Brownian motion and blood flow mainly.
Trying to mimic this condition, bioreactor experiment has been set up. The idea is
to use 3D insert to simulate a tridimensional structure of cells and to build a perfusion
bioreactor to mimic blood circulation condition.
The complete protocol permits to compare result of 3 different types of culture:
• static 2D culture (called S2): it is the regular method used in previous tests
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• static 3D culture (called S3): it very similar to S2 method but in this case cells
are not seeded on the bottom of well but are attached on the 3D insert and this
is leaved in a not treated for adhesion plate or in a petri dish
• dynamic 3D culture (called D3): the 3D insert described in S3 case is hold inside
a chamber connected to a perfusion pump that can simulate blood flow.
The first things to do are the selection of better 3D insert dependent on our
purpose and on methods used to reach it and the setting up of functional and practical
bioreactor.
The selected insert has to be a good 3D model that can show similar behavior than
tumor tissue and has to support adhesion, migration and proliferation of cells. It has
to be able to resist in static and dynamic condition and has to further proliferation,
morphology, distribution and viability of cells
In all steps of this experiment ES2 cell line has been used. The first choice of 3D
insert was fibroin sponge produced at Biotech/UNITN lab. These sponges are built
using salt-leaching method with NaCl particles (425-1180 nm). Sponge diameter is
6 mm and height is 4 mm. In figure 6.12-left there is a picture of them and of their
structure obtained by SEM. It is easy to notice the nanoporous structure of scaffold
with pore size between 10 and 30 um.
But this choice has shown problems and difficulties during the analysis. Sponges
are sensitive to dye and other reagents used in biological analysis but the main problem
is that each sponge is different to another one. So, these sponges have been abandoned
and a commercial 3d insert has been selected (3D Biotek 3D Insert PS scaffold, Sigma
Aldrich). These microfabricated inserts are in polystyrene (same material of regular
culture plate) plasma treated to promote cell adhesion (figure 6.12-right
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Figure 6.12: Left: SEM images of fibroin sponge, Right: optical images of 3d insert
The main characteristics are:
• Diameter: 5 mm
• Height: 0,5 mm
• Fiber size: 150 um
• Pore size: 200 um.
The most important skill of this insert is the type of material: it is transparent,
not sensitive for dye and reagents and each scaffold is similar to another one. This
fact is very important for reproducibility and uniformity of samples.
A perfusion bioreactor has to provide an appropriate environment for biological
organism. In most cases, a bioreactor is a container that allows chemical reactions of
micro-organisms or molecules derived from them. In a more specific way, a bioreactor
is an apparatus that can reproduce physiological condition, to maintain and promote
tissue regeneration (for example for growing of tissue of bone, cartilage, hearts and
blood vessel).
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In an advanced bioreactor, every culture condition can be modified to study their
influence on tissue growing. The main physiological conditions are:
• diffusion of nutrients: cell medium
• pH
• temperature
• concentration of CO2 and O2.
In particular bioreactors it is possible to apply mechanical and biochemical stimuli
to improve tissue properties. It is important for a bioreactor to guarantee sterility to
cell culture and to correct oxygenation; for this purpose all components of a bioreactor
must be sterilizable. To avoid contamination and growth of bacteria, filters for air and
solution (cell medium,...) are attached to entrances of apparatus. But these filters
and the polymer tubes have to further oxygen and CO2 transit.
Figure 6.13: First (left) and last (right) configuration of bioreactor used for dynamic
condition experiment
The developed bioreactor is a perfusion one; it has 8 polycarbonate chamber, 3-
way connections, PTFE (Polytetrafluoroethylene) tubes and flexible Tygon tube used
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with peristaltic pumps. Scaffolds are located inside the chamber where the medium is
flowed perpendicular to samples (perfusion). The medium flow is maintained constant
using a peristaltic pump and its direction is from bottom to top to avoid air bubbles.
Many bioreactor configurations have been tested to obtain good quality of perfu-
sion and reproducibility of experiments.
The first bioreactor is described in figure 6.13-left and the last one is showed in
the right part of the same image. There are big differences between them. The
first version has only one pump to perfuse fresh cell medium taken from a plastic
bottle into 8 chamber. For the main part of the experiment, injection of MNPs,
the fresh medium bottle was replaced with a bottle of MNP enriched cell medium.
The different flow pression in chambers and the large quantity of MNPs needed for
the experiment marked the failure of this bioreactor. After many test versions, the
ultimate bioreactor has been built (6.13-right). It has 2 peristaltic pumps, each with
4 channels. The total number of chambers is 8 and each chamber has a pump with
the same flow condition.
The working scheme of this bioreactor is described in figure 6.14-top and it has to
2 configurations:
• Seeding - No MNPs: the medium is taken from the bottle, passed by pump and
through the chamber and is trashed in another bottle (fig. 6.14-left).
• Testing - MNPs: the medium with MNPs is injected inside the chamber and the
apparatus is modified to create a recycle that brings MNPs inside the chamber
more times. This has two advantages: to reproduce the recycle of blood stream
and to save a large amount of MNPs (fig. 6.14-right).
For a better quality of analysis, the recycle is not close on the same chamber but
MNPs are mixed and pass in every chamber.
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Figure 6.14: Scheme of bioreactor: green tube is for recycle and brown tube is for
open configuration
About biological test, a large number of plates and inserts has been performed to
permit statistical analysis of each valuation:
• Cell proliferation with AlamarBlue kit
• Morphological behavior and viability with confocal microscope
• Internalization with confocal microscope and colorimetric molecules (ferrozine)
• Trypsinization and cell count
• Quantification of DNA.
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Each of these techniques is useful to characterize and understand the efficiency
and ability of our bioreactor and our experiments.
6.4.6 Bioreactor experiment: Results and Comments
2D Static
Proliferation: in figure 6.15 it is possible to notice that the proliferation of cells
increased in 4 days and after MNP injection the value is pretty much the same; the
small difference can be related to confluence of cells inside the well.
Figure 6.15: Proliferation of ES2 cells in static 2D culture, at different experimental
time. “1 day”: after 1 day of static culture; “4 days”: after 4 days; “5 days”: after 5
days (no MNPs); “4+1 days”: after 4 days of static culture and 1 day with MNPs
Morphology and MNP uptake with confocal microscope: in fig.6.16 it
possible to verify morphology and adhesion of cells. They are good and show good
health. Red spots are MNP labeled with a fluorescent dye (DiI). According with
figure it is possible to affirm that MNPs are inside the cells and not on the membrane
because there are not red spots in nucleus.
Trypsinization and cell count
Samples have been trypsinizated to remove cells from insert and to count them
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Figure 6.16: ES2 cells in 2d static condition and functionalized MNPs with DiI after
1 day. Magnification 60X. The 4 images is the 3 spectral component and merged
picture
with Cellmeter Auto-T4, Nexcelon Bioscience. This method is not so accurate, but
it is a quick way to discriminate alive and dead cells.
The obtained value is: (1, 0± 0, 2) ∗ 106 cells for well.
Quantification of DNA
To obtain this value a specific assay has been used. This method is very accurate
but counts both cells, alive and dead.
The obtained value is: (9, 4± 0, 4) ∗ 105 cells for well.
So from these results and the precedent one, it is possible to have complete infor-
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mation about viability and proliferation.
Internalization of MNPs
To obtain the value of MNP uptake for one cell, the amount of iron ions of sample
(calculated with spectrophotometric analysis with ferrozine) is correlated to number
of cells in sample. The number of cells is calculated using the one obtained with DNA
quantification calculated considering the viability measured with cell counter.
The obtained value is: (0, 8± 0, 1)pg/cell.
3D static and dynamic
To perform this part of work 2 cell cultures have been carried out at the same time:
3D in static and dynamic condition. The goal is the same of 2D static. For a further
control 2D cell culture has been performed.
Cells (1.5∗105) are seeded on 3D inserts of polystyrene in 96-well plate not-treated
for cell adhesion, moved after 6 hours in a 48-well plate and maintained in 37◦C and
5% of CO2 incubator.
For dynamic condition, the previously described bioreactor has been used. The
first part of protocol is the same of static condition, but after 6 hours inserts are
moved in chambers of bioreactor instead of 48-well plate.
Proliferation: From 6.17 it is possible to notice that proliferation of S3 increased
at day 4, hence it is a normal proliferation of cell. Then this value is constant until
day 5. Between day 1 and 4, D3 samples for D3, maintain a comparable value of
proliferation, but there is a reduction after 1 day. It is possible to explain the difference
between static and dynamic condition at day 4 taking into account the different
seeding environment. Probably static condition improves better proliferation respect
to dynamic one. Then the injection of MNPs does not change the cell behavior and
viability for S3 and D group either.
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Figure 6.17: Comparison between ES2 cell proliferation on a insert in static and
dynamic conditions. MNPs injection happens at day 4
Morphology and MNP uptake with confocal microscope: From both S3
(figure 6.18) and D3 (figure 6.19) images (left and right) it is possible to notice that
cells have a good adhesion on scaffold. Cells have a correct distribution and are
attached on fibers at different depth. Day by day each passing day there is increasing
of cell rug, that means health, good proliferation and migration. At day 5, red spots
show the position of dye-MNPs inside the cell around the nucleus. Injection of MNPs
does not change adhesion, morphology and distribution of cells.
Viability with confocal microscope
In figure 6.20, the red spots (PI) indicate dead cells and green dyes (FDA) indicate
alive cells. According to this, it is easy to affirm that, in the same way for S3 and D3
samples, the number of dead cell increased day after day. Also the injection of MNPs
does not raise the number of dead cells.
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Figure 6.18: Upper: Polystyrene insert, ES2 cell line, static condition, day 4. Mag-
nification 20x and 3d reconstruction. Down: Polystyrene insert, ES2 cell line, static
condition, day 5 after MNP injection. Magnification 20x and 3d reconstruction
According to the proliferation results, cell death is a physiological condition of cell
seeding process.
Trypsinization and cell count: Polystyrene inserts are trypsinizated to remove
cells and to count them with Cellometer Auto-T4, Nexcelon Bioscience. This method
is not so accurate, but it is a quick way to discriminate alive and dead cells. For a
complete analysis S2 values are reported too.
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Figure 6.19: Upper: Polystyrene insert, ES2 cell line, dynamic condition, day 4. Mag-
nification 20x and 3d reconstruction. Down: Polystyrene insert, ES2 cell line, dynamic
condition, day 5 after MNP injection. Magnification 20x and 3d reconstruction
The obtained values are:
Samples Cell number
D3-MNP (8± 2) · 104
S3-MNP (2.2± 0.7) · 105
S2-MNP (1.0± 0.2) · 106
DNA qualification:
To obtain this value a specific assay has been used. This method is very accurate
but it counts both cells, alive and dead. For a complete analysis S2 values are reported
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Figure 6.20: A. Insert for live(green)-dead (red) analysis at day 1; B. Same as A at
day 4; C. Same as A at day 5 after MNP injection; D. Insert moved in bioreactor at
day 4; E. Same as D. at day 5 after MNP injection;
too.
The obtained values are:
Samples Cell number
D3-MNP (1.97± 0.04) · 105
S3-MNP (2.9± 0.4) · 105
S2-MNP (9.4± 0.7) · 105
Internalization of MNP
To obtain the value of MNP uptake for one cell, the amount of iron ions of sample
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(calculated with spectrophotometric analysis with ferrozine) is correlated to number
of cells in sample. The number of cells is calculated using that obtained with DNA
quantification calculated taking into account the viability measured with cell counter.





Figure 6.21: Recap of all experiments: amount of iron ions in picogram for 1 cell
Figure 6.21 shows a comparison of uptake results for 3 samples: S2, S3 and 3D.
It is possible to notice that ES2 cells internalize in a tridimensional model the same
quantity of MNPs for both culture conditions: static and dynamic. The amount of
2D samples is lightly less but in the same order of magnitude. But the value of S2
sample (cell on the bottom of well) is probably overestimated because the bottom
and wall of the well can absorb MNPs, which increase the total signal.
Inserts do not suffer for the same problems, because it is possible to move them
from the place where the experiment has been carried on. To obtain better result for
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each group (S2, S3 e D3) a lot of blank samples have been prepared: wells with cells
and without MNPs, inserts with cells and without MNPs, inserts with MNPs and
without cells.
It possible to affirm that cells in a 3D model slightly aim to internalize MNPs
easier respect to cells in a 2D model. The substitution of a 3D culture instead of a 2D
model does not show disadvantage, leak of information or efficiency. There is the same
behavior also changing the culture condition (static and dynamic); hence performing
experiments in dynamics condition does not compromise this measurement.
Rather, the bioreactor has physically flexible components and adjustable charac-
teristics: flow speed, the possibility of having different circuit (close, to lose and with
inter-connections). That makes possible the design of different bioreactors for sev-
eral types of experiments: gradient of MNPs concentration tunable at different time.
Moreover it is possible to use the bioreactor for other samples instead of nanoparticles




Ferrozine protocol applied to ex vivo analysis
According with recent literature, most used techniques to verify the presence of iron
oxide nanoparticles in the tissue are histology, electron microscopy or nuclear magnetic
spectroscopy. About these methods there is a large amount of papers or books.
On the contrary, it is very difficult to find work about a precise quantitative
characterization of MNPs inside the tissue.
In In vivo situation the analysis is very complicated, but also ex vivo it is not easy
to find standard procedures.
The idea developed in this section is to exploit the ferrozine protocol (described
in section 5.1.6) to measure the amount of iron ions inside the tissue. In literature
there are not papers describing a ferrozine-based procedure to quantitative measure
the uptaken MNPs by tissue.
To do this, frozen pieces of liver, kidney and tumor from LBI-CR research group
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have been used. These pieces have been cut in smaller pieces to have the possibility
to carry about many trials.
The possible ways to effect this process have been reduce to two and called:
• “brute force”: the tissue sample is destroyed and burned with high concentrated
HCl for a long time. In this way tissue, cell, protein and MNPs are disrupt and
iron ions from MNPs are measured with ferrozine protocol.
• “clever trick”: different molecules (as Proteinase K) are used to disrupt just
protein and dissemble the tissue or tryspin are used to recover cell to analyze
in the same way described in section 6.4.3.
For “brute force” the HCl solution with the tissue has been heated up with a
silicon oil bath or in oven for 16 hours at 120◦C. For “clever trick” proteinase K and
trypsin (used in cell culture) have been used. To help this molecules the samples have
been homogenized with an electrical homogenizator.
Besides the tissue, an iron ion solution has been tested to verify the possible
false-negative or false-positive results.
Figure 7.1 shows the result of use both of these techniques on a pieces of liver
taken from mice treated with AB-MNPs and engrafted with HCT116 and HT29 cell
lines
It is possible to notice that there are signals from oil and oven techniques for MNPs
and control liver and from iron ion solution. There are not signals from “proteinase
K” and Trypsin spending more time and homogenizing the samples.
For these techniques a problem with the pH occurs. The ferrozine molecule works
fine in a narrow pH range, probable buffer of these molecules move the pH of final
solution and it is not possible to have a signal.
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So taking into account the result of HCl oil bath and oven, another explorative
experiment has been carried out.
In this case, there is a comparison of these two techniques using liver, kidney and
iron ion solution as samples to analyze.
In figure 7.2 it is possible to notice that the results of “oil bath” and “oven” are
pretty similar in behavior and value.
So taking into account the facility of experiment preparation and reproducibility,
the “oven” method has been selected to better analysis to try to quantify the amount
of MNPs in tissue.
Until now, just one experiment has been carried out: uptakes of MNPs by liver
after 4h and 24h have been compared. The procedure is schematized below:
• Total used liver samples were 7: 1 as a control, 3 for 4h analysis and 3 for 24h
• Each sample two little pieces (about 20 mg) were taken
• Each pieces was disrupt with HCl at 120◦C. Each piece was separated respect
to similar one
• After 16 hours, two small aliquots (50 ul) from the same solution were used to
measurement of iron ion amount with ferrozine method
• At the end of ferrozine protocol, two duplicates were measured at 562 nm in
absorbance
According with this protocol for each mouse 8 measures have been performed. So
according with the first point of previous list, there are 8 measures for the control
and 24 measures for both 4h and 24h analysis.
Figure 7.3 shows the graph of amount of iron ion (µg) uptaken by 1 mg of tissue.
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It is not easy to see big difference between 4h and 24h samples. There is a little
distinction between control and MNP treated sample.
On possible reason for this difference is that the analysis is not on the entire organ
(liver in this case) but just on a small section of it. Probably the large distribution
of value depends on this fact, indeed larger distributions is for treated MNPs not for
the control. Probably the MNPs can not diffuse homogeneously into tissue and the
final value of uptake depends on the section that has been taken.
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Figure 7.1: Uptake measurement of MNPs by liver tissue calculated using different
methods (“oil bath”, “oven”, with proteinase K and trypsin) based on ferrozine pro-
tocol. Sample are: MNPs treated liver tissue, control liver tissue and standard iron
ion solution
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Figure 7.2: Uptake measurement of MNPs by liver and kidney tissues calculated using
different methods (“oil bath” and “oven”) based on ferrozine protocol. Sample are:
MNPs treated liver and kidney tissue, control liver and kidney tissue
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Figure 7.3: Uptake measurement of MNPs by liver tissues calculated using “oven”
method based on ferrozine protocol. Sample are: 4h and 24h MNP treated liver and
control liver tissue. The spots are the single value, the long central bar is the sample
mean and other bars are the standard deviation of the sample
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Conclusions
The production of iron oxide nanoparticles with the ability to be used as contrast
agent and as drug delivery carrier was the first purpose of the Nanosmart project.
This implied several secondary objectives: indeed, we needed to verify if our MNPs
satisfied specific characteristics. To be an effective contrast agent, they have to show
high magnetic properties and they have to be biocompatible, but not to be recognized
as foreign bodies by the immunity system they must be biomimetic. Moreover, to be
a good carrier for drug delivery, MNPs must have good drug entrapment capability
and controlled cell interaction.
Just after verifying and reaching these abilities, it would be possible to affirm the
realized MNPs are an excellent tool for tumor diagnostics and therapy.
The purpose of this thesis work was an in-depth characterization of every single
potentiality offered by iron oxide nanoparticle. According to the characteristics de-
scribed in section 2.2, several analysis were performed, permitting the design and the
production of the best possible structure.
The first challenge was the investigation and the improving of the synthesis and
functionalization of MNPs; we demonstrated the accuracy and the reliability of such
techniques towards MNPs production. According to our results MNPs came out to be
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a complex structure, stable in different buffers at various temperatures and different
concentrations. However, these nanoparticles showed also a very modular structure,
in which it was not difficult to change the size of iron oxide inner core or to select
different thickness or particular electrical charge of external layers.
Further, these nanoparticles also exhibited a high value of magnetic relaxivity r2,
comparable with that of commercial products; so it is possible to affirm that MNPs
can be effectively used as MRI contrast agents.
A critical milestone for the project was the verification of the biocompatibility of the
nanoparticles. Several studies demonstrated that MNP are not toxic, however, there
was just a collateral effect: the cell proliferation was retarded in presence of MNP.
Another result to underline is the measure of MNP uptake by cells. The most in-
teresting point is that nanoparticles with EGFr antibody entered easier within the
cells that had high gene expression for EGFr respect to nanoparticles without the
antibody. On the contrary, nanoparticles without antibody entered easier into cells
with a negative gene expression for EGFr respect those with antibody.
The drug loading is still an open aspect of this work. Only in the last months, re-
search attention has been focused on this topic. Preliminary results seem promising;
nonetheless, it is important to improve DOX loading into MNP and to verify its re-
lease and in vitro effectiveness.
One of the most stimulating and riveting aspects of this work has been the design
and fabrication of a perfusion bioreactor. According to the results in this thesis work,
it is possible to affirm that this apparatus, combined with the use of the 3D cell cul-
ture insert, enables for an environment capable to simulate a native tumor tissue and
blood stream conditions as would be expected for MNPs uptake.
The last and the most important milestone has been the preliminary in vivo verifica-
tion of MNP ability. Here we confirmed that MNP can spread over the tumor region
167
within as little as 4 hours from injection. Histology also demonstrated that MNPs do
not have adverse interaction with kidney tissue. According to these results the liver
accumulated MNPs, thereby indicating it is the first mechanism to remove MNP from
the blood stream.
Regarding the tumoral uptake, there is not a significant difference between 4h and
24h uptake, also for MNP and AB-MNP samples. The dominant variable in this
case seems to be the EGFr gene expression, AB-MNPs entered with slightly higher
difficulty the HCT116 cells (intermediate EGFr gene expression) with respect to raw
MNP, while AB-MNP entered the HT29 (high EGFr gene expression) easier than raw
MNP.
According to these promising, but still preliminary results, it is possible to hy-
pothesize that our nanoparticles have a chance to become in a future a commercial
product, usable both for diagnostic and therapeutic applications. Just this double
ability is the main strong point of our nanoparticles, beyond the modularity and fa-
cility of production.
In the next months, an experiment to verify the tumor shrinking will be performed
using the complete MNP structure: iron oxide nanoparticles loaded with DOX drug
and functionalized with EGFr antibody.
This experiment will indeed shed further light onto the efficacy of MNPs for tumor
therapies, giving us a key proof that could, eventually, open the door to the years-long
clinical trials.
168 Conclusions
In conclusion, these data offer substantial promise and encouragement to continue
the work on this research field using this structure and methodology. With improve-
ment and better analysis the MNPs here designed, fabricated and validated may offer
considerable interest to the scientific community, in particular with regard to tumor
therapies.
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